Review

The Pulmonary Surfactant System: Biochemical and Clinical Aspects

L. A. J. M. Creuwels, L. M. G. van Golde, and H. P. Haagsman

Laboratory of Veterinary Biochemistry, Utrecht University, P.O. Box 80176, 3508 TD
Utrecht, The Netherlands

Abstract. This article starts with a brief account of the history of research on pulmonary surfactant. We will then discuss the morphological aspects and composition of the pulmonary surfactant system. We describe the hydrophilic surfactant proteins A and D and the hydrophobic surfactant proteins B and C, with focus on the crucial roles of these proteins in the dynamics, metabolism, and functions of pulmonary surfactant. Next we discuss the major disorders of the surfactant system. The final part of the review will be focused on the potentials and complications of surfactant therapy in the treatment of some of these disorders. It is our belief that increased knowledge of the surfactant system and its functions will lead to a more optimal composition of the exogenous surfactants and, perhaps, widen their applicability to treatment of surfactant disorders other than neonatal respiratory distress syndrome.

Key words: Surfactant protein—Pulmonary surfactant—Respiratory distress syndrome.

History

Research on surfactant goes back to 1929 when von Neergaard published the first paper about the difference in pressure needed to inflate lungs with air or with liquid [333]. He found that the pressure necessary for filling the lungs with air was higher than when the lungs were filled with liquid. To explain this result he stated that the alveoli were stabilized by lowering the naturally high surface tension of the air/water interface. In 1946 Thannhauser and co-workers reported that lung tissue has a remarkably high content of the lipid dipalmityl lecithin (current name, dipalmitoylphosphatidylcholine)
At that time no connection was made between the high content of this lipid and stabilization of the alveoli. Nine years later, in 1955, Pattle proposed that bubbles, made of lung fluid material, obtained their stability through the quantity and quality of the surface-active material [246]. Subsequently, Clements showed, with the help of a modified surface balance, that surface tension dropped to low values upon compression of surface films from lung extracts [41]. This was followed by a theoretical attempt to clarify the role of surfactant in the structural stability of the lung [42].

It was also the group of Clements which investigated for the first time the surface tension-lowering properties of several lipid fractions. These investigators found that it was the phospholipid fraction that reduced the surface tension and that this reduction was inhibited by other lipid fractions (cholesterol, triacylglycerols, and fatty acids). In the same paper it was reported that the activity of synthetic dipalmitoylphosphatidylcholine (DPPC) was similar to that of phospholipids isolated from fresh beef lung [172]. In the meantime, Avery and Mead showed that the surface tension of lung extracts of infants under 1,100–1,200 g and of those dying with hyaline membrane disease was higher than expected [10]. They associated this with surface-active material deficiency.

In 1967, it was shown that DPPC was produced during the development of the lung and secreted into the alveolar space [93]. A few years later a diagnostic test, using the lecithin/sphingomyelin ratio of amniotic fluid, was developed to determine the maturity of the fetal lung [92]. In 1975 Hallman and co-workers discovered the importance of phosphatidylglycerol (PG) in contributing to surfactant spreading and the decreased levels of this phospholipid in children suffering from respiratory distress syndrome (RDS) [112]. The demonstration of a protein in surfactant was important for the recognition that proteins could be important constituents of surfactant [171]. A landmark was the first successful treatment of neonatal RDS with surfactant replacement therapy [87]. Next, it was recognized that lipid extracts alone were not sufficiently efficient, and attention was focused on the presence and role of proteins in surfactant. This resulted in a rapid extension of research to get insight into the molecular biology, structure, and properties of pulmonary surfactant proteins. In 1988 a new nomenclature for surfactant proteins was proposed: the proteins were termed surfactant protein A, B, and C [257]. Consequently, a newly discovered protein, which is, at least partly, associated with surfactant phospholipids, was named SP-D [250]. Apart from the biophysical role of surfactant, it became clear that surfactant had also a role in lung defense [320].

Although our knowledge of the composition of surfactant and the structure of the surfactant proteins has advanced greatly, the various functions of the surfactant proteins remain incompletely understood. Nonetheless surfactant has been introduced in clinical treatment with much success [278].

Anatomic Aspects of the Lung

The lung is a large organ (6% of the body volume, irrespective of the body weight) with a large inner surface, continuously in contact with the environment. Mammalian lungs are membranous sacs, divided into alveoli, small sacs that vastly increase the surface
area available for gas exchange. Measurement of the surface of the human lung indicates that 1 cm³ of lung tissue has a total gas exchange surface of 300 cm². Because warm blooded animals require a high rate of oxygen uptake, the large surface is essential [275].

Gas exchange in the lung takes place in the alveoli; the bronchi and their branches are only connective tubes. The alveoli are bubble-shaped, and have a high curvature (Fig. 1). Oxygen diffuses from the alveoli to the capillaries, and carbon dioxide leaves the capillaries and diffuses into the alveoli. The surface tension of the moist inner surface originates from the attraction between the molecules in a fluid and is responsible for the tendency to make the bubbles contract and eventually disappear. Without prevention this would result in lung collapse. This tendency is minimized by the presence of a substance that reduces the surface tension on the inner surface of the alveoli to very low values. Although it is sometimes stated that this value is near zero, it is theoretically impossible to eliminate surface tension completely [15, 16]. The surface tension lowering substance, which is found in the lungs of all mammals, is called lung surfactant. Clements demonstrated that the tension of a surface film varies with the surface area [41]. Exhalation results in a decreased surface area and a decreased surface tension, whereas a relatively high surface tension is found when the surface area of the lung is large (after inhalation). This mechanism prevents the alveoli from collapsing during expiration.

Composition of Surfactant

Surfactant is produced by the alveolar type II cells in the lung. Two major surfactant pools can be distinguished: an intracellular surfactant compartment and an extracellular surfactant compartment. The intracellular compartment consists of the lamellar bodies in the alveolar type II cells. Their function is storage of surfactant before it is released into the alveolar space [105, 314]. The extracellular surfactant compartment is surfactant that is secreted into the alveolar space. Collection of this surfactant is done easily by bronchoalveolar lavage.

When (extracellular) surfactant from several species is compared, a highly consistent chemical composition is seen [46, 258]. Pulmonary surfactant is composed of two main fractions: lipids and surfactant-specific proteins. Lipids account for approximately 90%, and phospholipids from the bulk of the lipids. Other lipids that are found are: cholesterol, triacylglycerol, and free fatty acids. Phosphatidylcholine (PC) is identified as the most abundant component of surfactant and is always found in a quantity of 70–80% of the total amount of lipid. Approximately 50–70% of PC is saturated, especially in the dipalmitoylated form (DPPC). The anionic PG accounts for approximately 8%. Other lipids are phosphatidylethanolamine (PE, ±5%), phosphatidylinositol (PI, ±3%); and phosphatidylserine (PS), lysophosphatidylcholine, and sphingomyelin in small quantities (less than 2%) [46, 94]. The plasmalogen analog of PC has been identified as an important component in pulmonary surfactant [262]. Cholesterol accounts for 2.4 weight% of the total composition of surfactant [258]. The phospholipid composition of the lamellar bodies is very similar to the composition of the extracellular compartment [3, 146, 239].
Fig. 1. A, schematic drawing of lung tissue. B, type II cells produce surfactant, which is stored in lamellar bodies (1) and secreted into the alveolar space (2). The surfactant is transformed (3) into tubular myelin (4), from which the monolayer (5) is formed. After the surfactant is used, it is taken up again (6) by the type II cells and reused (7).
Although most of surfactant consists of lipids, it comprises approximately 10% protein. Four surfactant-associated proteins have been described (for a review; see Ref. 150). These proteins can be divided into two groups: the hydrophilic surfactant proteins SP-A and SP-D, and the hydrophobic surfactant proteins SP-B and SP-C. The surfactant proteins are either exclusively lung associated or predominantly found in the lung. SP-A and SP-D may play important roles in the first line defense against inhaled pathogens, and SP-A may have a regulatory function in the formation of the monolayer that lowers the surface tension. In 1972 King and Clements reported that canine surfactant lipids were able to form stable surface films with low surface tension but that this process was much faster when complete canine surfactant with the proteins included was used [170]. This important observation indicated that the presence of the surfactant-associated proteins was required for an optimal functioning of the lung.

**Regulation of Phospholipid Synthesis and Secretion**

The lamellar bodies contain all lipid and protein components of surfactant [17, 235] and are secreted into the fluid layer lining the alveoli (Fig. 1). Several factors influence surfactant phospholipid synthesis and secretion (for reviews, see Refs. 19 and 201. Some investigations to determine physiologic and pharmacologic regulation of surfactant secretion have been carried out with the intact lung (whole animal and perfused lung), allowing the involvement of nerve influence, paracrine factors, and physical forces. However, most experiments designed to study regulation of surfactant secretion have been performed with isolated type II cells that had been cultured overnight in the presence of labeled choline. Subsequently, secretion is quantified by measurement of the amount of radioactivity accumulated in lipid extracts of cell media and expressed as the percentage of label secreted. Secretion is stimulated by mechanical stretch and various agents, including agonists for β-adrenergic, purino-, and vasopressin- receptors, and is associated with increased cytosolic Ca\(^{2+}\), cellular cAMP, and activation of protein kinases. The reader is referred to reviews for further information on the regulation of surfactant secretion [37, 201, 349]. Interestingly, the composition of surfactant phospholipids can be influenced by factors such as diet [21, 241], age [232], and physical effort [66, 237].

**Extracellular Surfactant Metabolism**

After secretion, surfactant is transformed into specific structures, called tubular myelin, from which insertion of phospholipids into an air-liquid interface is thought to take place (Fig. 1). The thickness of the alveolar lining liquid layer in the rat lung is 0.24 μm, with a variation of 25 nm to some micrometers [18]. The phospholipid molecules are found with their hydrophobic fatty acid chains up in the air and their (polar) headgroups in the subphase. The fatty acid chains are tilted at an angle of 21.5 to 29°, depending on the relative humidity [162]. Surfactant phospholipids form stable surface films with low surface tension upon compression; adsorption of phospholipids from the subphase into the surface film is highly accelerated when hydrophobic surfactant proteins are present [121]. Phospholipid adsorption is required to ensure molecular
occupation of the air-water interface during inflation of the lung. Not only is the formation of the monolayer stimulated by the hydrophobic proteins, but it has been reported that SP-B alone may also reduce the surface tension by increasing the lateral stability of the phospholipid layer [43]. The composition of the monolayer is also an important factor in the adsorption of the surface-active material into the monolayer [234, 355].

During expiration the surface tension at the air-water interface of the lung is reduced. To reach a low surface tension, the monolayer becomes enriched in DPPC. This process may occur either by selective insertion of DPPC during adsorption or by selective exclusion of other components of the surface film during reduction of the surface area. Evidence of the latter possibility, which results in the formation of different types of remnants, has been provided [245, 276]. During the next inhalation, and expansion of the surface area of the alveoli, the hydrophobic surfactant proteins improve the respreading of lipids [234, 303]. During this process surfactant components are lost from the interface and taken back into the type II cell for recycling.

Hydrophilic Surfactant Proteins

Two hydrophilic surfactant proteins have been isolated, SP-A and SP-D. These two proteins are related and belong to a subgroup of mammalian lectins called collectins (or C-type lectins, group III). This is a group of soluble proteins which consists of oligomers with COOH-terminal carbohydrate recognition domains in association with NH₂-terminal collagen-like domains. The collectins can be divided into a group with a bouquet form (mannan-binding protein, SP-A) and a group with a cruciform shape (conglutinin, SP-D) [69, 130]. SP-A and SP-D may be involved in the first-line defense system of the lung [313].

Structure of SP-A

The predominant surfactant-associated protein is the large and complex glycoprotein SP-A (Fig. 2). Almost all of the protein in bronchoalveolar lavage is found associated with surfactant lipids. SP-A was the first of the surfactant proteins that was purified [171] and analyzed for its primary structure [343]. Butanol extraction is a widely used method to purify SP-A, but recent work from our laboratory suggests that some of the functional characteristics of SP-A are lost during this extraction procedure [317]. The molecular mass of the monomeric form is 28–36 kDa, and human SP-A comprises 248 amino acid residues [341]. When comparing the primary structure of SP-A from several species (human, dog, rabbit, rat, mouse), the homology is striking [26, 29, 175, 273, 343]. The primary structure of SP-A comprises four domains: an amino-terminal domain, a collagenous domain, a neck domain, and a carbohydrate recognition domain (CRD). The amino-terminal segment of secreted SP-A is a short peptide of 7 amino acids, with a cysteine residue at position 6 which forms an interchain disulfide bond. This cysteine may help to align SP-A subunits during assembly of the mature oligomers. In some species (e.g. rat, dog)
a potential glycosylation site has been detected in this area, whereas in other species (human, rabbit) no glycosylation site is present.

The next part of SP-A is a 73-amino acid collagen-like segment, consisting of 23 repeating tripeptides with the sequence glycine-Xaa-Yaa (in 13 of the 24 triplets, Yaa is hydroxyproline), only interrupted between the 13th and the 14th Gly-Xaa-Yaa triplet as a result of a proline residue, and the substitution of a cysteine for a glycine in the triplet sequence [119]. This region is folded as a triple helix involving three highly homologous subunits. Six of these triple helices are assembled into a bundle of 18 monomers of SP-A. Electron microscopic images of SP-A obtained after rotary shadowing indicate that this region of SP-A is organized into a rod-like structure of approximately 20 nm. The interruption in the collagen-like repeating sequence after the 13th triplet introduces a flexible kink in the collagen rod. After this interruption, the trimers are no longer bundled, but they bend outward from the central axis into six directions [338]. The carboxyl-terminal region (divided into a neck region and the CRD) is composed of 148-residues, forming a C-type lectin domain [67, 68].

The neck region may be involved in phospholipid binding [269], although this domain cannot account for all the lipid binding activity of SP-A [230]. Epitope mapping indicated that the CRD is also involved in lipid binding of SP-A [183], and especially the region Glu\textsuperscript{202} to Met\textsuperscript{207} is important for expression of the biologic activities [127]. The CRD contains a Ca\textsuperscript{2+}-dependent specific carbohydrate binding site

Fig. 2. Structure of SP-A.
The positions of the four cysteine residues in this region are conserved in all members of the class of calcium-dependent lectins. Disulfide bonds have been described between residue 135 and 226, and residue 204 and 218 [106], and their function is probably stabilization of the structure. The CRD is glycosylated at position 187. The carbohydrate moiety may be involved in lipid aggregation [102] and virus recognition [25, 319].

Properties of SP-A

SP-A was the first surfactant-associated protein discovered, and the properties and putative functions of SP-A (Table 1) were studied more extensively than those of the other surfactant proteins. Obviously, SP-A is not directly responsible for the surface tension lowering properties of pulmonary surfactant, although SP-A has possibly a regulating role [121, 276]. The fact that excess SP-A could be detected in tracheal and bronchial glands and in the epithelium of conducting airways [169] also suggests the importance of non-surfactant-associated functions of SP-A and contributes to the proposed role of SP-A in the host defense. SP-A (and SP-D) may even have a function in the amniotic fluid in the antibody-independent recognition and clearance of pathogens [212].

Formation of Tubular Myelin

In bronchoalveolar lavage, surfactant exists as various morphologically different complexes. Pulmonary surfactant is transformed into tubular myelin after the secretion of lamellar bodies into the fluid layer, which lines the alveolar space (Fig. 1). In tubular myelin, SP-A is localized at the corners of the tubular myelin lattice [334]. The phospholipids and proteins are thought to be stored extracellularly in this structure before they are used to incorporate phospholipids into the monolayer that lines the alveoli [94]. By in vitro reconstitution, it became clear that SP-A is essential for the formation of this lattice [259, 301, 347]. SP-A aggregates lipid vesicles in a calcium-dependent manner [104, 120]. SP-A-induced aggregation is dependent on an intact collagenous domain [269]. At physiologic extracellular Ca\(^{2+}\) concentrations SP-A shows self-aggregation [104]. These interactions and radial SP-A–SP-A interactions via the CRD and oligosaccharide moiety may be important for the SP-A-induced formation of tubular myelin [102]. The formation of large membrane structures could

| Table 1. Putative functions of SP-A |
|------------------------------------|
| ● Formation of tubular myelin |
| ● Regulation of phospholipid insertion into the monolayer |
| ● Modulation of uptake and secretion of phospholipids by type II cells |
| ● Activation of alveolar macrophages |
| ● Binding and clearance of bacteria |
| ● Binding and clearance of viruses |
| ● Chemotactic stimulation of alveolar macrophages |
be important to protect surfactant from inactivation by serum proteins. In line with this notion is the observation by Cockshutt and co-workers that SP-A reverses inhibition of the surface activity of lipid extract surfactant by serum proteins in vitro [47]. In lungs of patients with RDS a lack in tubular myelin is found together with a shortage of SP-A, supporting the importance of SP-A in tubular myelin formation [58].

**Regulation of Phospholipid Insertion into the Monolayer**

SP-A is also considered to play a biophysical role as a regulator of phospholipid insertion into the monolayer. This function is probably related to tubular myelin formation. The addition of SP-A to hydrophobic surfactant components leads to an enhanced phospholipid adsorption in vitro [39, 121, 276]. SP-A is able to bind to phospholipids in a calcium-independent way. Lipid binding requires the lipids to be in the gel phase [35]. In addition, SP-A has a high affinity for DPPC as was determined by binding studies on thin layer chromatography plates [181] and by fluorescence studies [35]. These properties may be important for enriching the surface film with DPPC during hydrophobic surfactant protein-induced insertion of phospholipids into the monolayer.

**Modulation of Phospholipid Uptake and Secretion**

Another physiologic function of SP-A may be the regulation of surfactant homeostasis [341, 349]. SP-A binds specifically to type II cells [182, 348] and inhibits secretion of labeled PC from these cells [65, 264]. It has been shown that the carboxyl-terminal domain of SP-A is responsible for the binding to type II cells, thereby regulating phospholipid secretion [230]. Results, mainly from studies with isolated type II cells, suggest that the removal of phospholipids from the alveoli by alveolar pneumocytes may be enhanced by SP-A [20, 308, 350, 354]. Several type II cell molecules have been described which bind SP-A, but so far none of these molecules was shown to be a functional receptor. Local concentration-dependent uptake rather than SP-A receptor-mediated endocytosis could be the explanation for the effects of SP-A on lipid uptake [101]. Part of the clearance of lipids is done by alveolar macrophages, and this process is also enhanced by SP-A [352].

**Activation of Alveolar Macrophages**

Human SP-A, purified from the lavage of alveolar proteinosis patients, enhances the lucigenin-dependent chemiluminescence response by rat alveolar macrophages [320]. In addition, the chemiluminescence response induced by rat surfactant can be abolished by antibodies against SP-A. These observations indicate that SP-A may also induce killing of microorganisms. The SP-A-induced stimulation of superoxide radical production is not observed with peritoneal macrophages, polymorphonuclear leukocytes, or monocytes [320]. SP-A surface interactions are required to release oxygen radicals from alveolar macrophages in vitro [342].
Clearance of Bacteria

Drickamer and co-workers described a sequence similarity between SP-A and mammalian-binding proteins and suggested that SP-A could also have carbohydrate binding properties [68]. Shortly afterward, calcium-dependent binding of SP-A to monosaccharides was described [103]. Ba\(^{2+}\), Sr\(^{2+}\), and Mn\(^{2+}\), but not Mg\(^{2+}\), could also substitute for Ca\(^{2+}\). As each human SP-A monomer binds two to three calcium ions, an assembled SP-A molecule binds 36–54 calcium ions [104]. It was proposed that SP-A may play a role in the lung defense [103]. Two reasons supported this notion: SP-A is able to bind carbohydrates, and SP-A is structurally similar to C1q. Evidence was found that SP-A potentiates the antibacterial functions of the alveolar macrophages but not of peritoneal macrophages, polymorphonuclear leukocytes, or monocytes [306, 320]. This is possible because SP-A can bind both bacterial components and alveolar macrophages. SP-A recognizes and binds endotoxin (also known as lipopolysaccharides or LPS) on the membrane of Gram-negative bacteria [157, 315]. The lipid A region of LPS has been implicated in the calcium-dependent binding of SP-A to Gram-negative bacteria [315]. The opsonization of bacteria is selective; e.g., *Staphylococcus aureus* is opsonized, but *Streptococcus pneumoniae* is not [206]. Recently, it has been shown that only rough LPS-containing bacteria are opsonized [254]. The killing of *S. aureus* is mediated by the binding of SP-A to the C1q receptor of monocytes [90]. Apart from opsonization, SP-A is also able to aggregate type A, but not type B, *Hemophilus influenzae* [206].

The growth of group B streptococci, intratracheally inoculated, was mitigated by treatment with surfactant devoid of SP-A [124, 285], indicating that other surfactant components also have bactericidal activity. The presence of SP-A potentiates the antibacterial functions of alveolar macrophages [177] by modulating the immune cell function in the lung by regulating the cytokine production and immunoglobulin secretion [176].

Clearance of Viruses

SP-A has also been reported to act as an opsonin in the phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages [318]. Compared with the opsonic capacity of serum, SP-A was found to be twice as potent. SP-A binds herpes simplex virus, as was shown indirectly by the increased binding to virus-infected cells expressing viral proteins at the cell surface [319]. Binding of SP-A to infected cells is inhibited by heparin, but not by yeast mannan. Interestingly, deglycosylated SP-A, obtained by digestion with N-glycosidase F, did not bind to infected cells. These observations suggest that the carbohydrate moiety of SP-A is involved in recognition of viruses [319]. The carbohydrate moiety is not required for macrophage stimulation. Benne and co-workers found recently that the carbohydrate moiety of SP-A is also involved in virus neutralization. Infection of LL-C MK2- cells with influenza A (H3N2) virus was prevented by preincubation of the virus with SP-A. Viral infectivity was measured by the appearance of viral proteins on the cell surface. After removal of the carbohydrate moiety of SP-A by enzymatic digestion with N-glucosidase F, SP-A no longer prevented viral infection.
of the cells. It was shown that SP-A binds to influenza A virus via its sialic acid residues and thereby neutralizes the virus [25]. SP-A may bind influenza virus partly via interaction with neuraminidase [200].

**Stimulation of Alveolar Macrophage Chemotaxis**

Wright and Youmans reported that SP-A stimulated alveolar macrophage migration. As the migration is directed into one specific direction, it is called chemotaxis [351]. This mechanism may contribute to the direct attack of the invaded microorganisms.

**Structure of SP-D**

The other hydrophilic collagenous glycoprotein found in bronchoalveolar lavage is SP-D (Fig. 3) [251]. It may be argued that SP-D is not a true surfactant protein. Only a small part of SP-D (less than 10%) is associated with surfactant phospholipids [250], and the production of SP-D is not exclusively in the lung; SP-D mRNA is also found in gastric tissue [83]. The mature human SP-D polypeptide chain contains 355 amino acid residues, and the molecular mass of this protein is 43 kDa under reducing conditions [198]. SP-D has many structural characteristics in common with other C-type
lectins such as SP-A and conglutinin. The nucleotide sequence of SP-D contains 87% nucleotides in positions similar to those of bovine conglutinin [192]. Like SP-A, the monomeric subunit of SP-D consists of four regions: a short amino-terminal sequence, a collagen domain that comprises 59 Gly-Xaa-Yaa repeats, a short neck region, and the carboxyl-terminal CRD. The collagen domain of SP-D is larger than that of SP-A (59 Gly-Xaa-Yaa repeats vs 24 Gly-Xaa-Yaa repeats, respectively) [199]. A second difference is that the collagen domain of SP-D is very regular, without the interruption caused by an extra proline residue, as is found in SP-A. This results in a stretched structure without a bend [99]. Collagen triple helices can cluster in a tail-to-tail conformation, forming dimers/trimers/tetramers of collagenous chains. A tetramer consists of 12 polypeptide chains and has a molecular mass of 630 kDa under nondissociating conditions. Electromicroscopy reveals a highly homogenous quaternary structure of SP-D in the form of a cross, which is very similar to conglutinin. From the central point (hub), four identical rod arms of 46 nm emanate and end in a globular terminal expansion, consisting of the CRD of three SP-D molecules [53, 198].

**Properties of SP-D**

SP-D does not seem to have a role in the classical function of surfactant. Most putative functions described so far are related to lung defense (Table 2).

**Binding of Bacteria and Activation of Alveolar Macrophages**

SP-D is a calcium-dependent lectin-like protein that associates with carbohydrates; it binds especially to α-glucosyl residues [249]. It has been demonstrated that SP-D binds to LPS of several bacteria (*Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella paratyphi*, and *Pseudomonas aeruginosa*), but not to Gram-positive *S. aureus* [179, 190]. SP-D can also bind with a high affinity to alveolar macrophages, and it induces production of oxygen radicals by alveolar macrophages [212, 316]. The binding of SP-D to both bacteria and alveolar macrophages and the subsequent induction of oxygen radicals could be very important in lung defense. SP-D may also scavenge free LPS (endotoxin). This would prevent the binding of LPS to granulocytes and would consequently protect against septic shock.

**Bacterial Agglutination**

SP-D has an ideal shape for agglutination reactions. The four clusters of CRDs at the end of the arms span a long distance, a feature that may be important for the agglu-
Agglutinated bacteria may be cleared more rapidly from the lung via mucociliary transport.

Protection against Nonbacterial Microorganisms and Viruses

Recently, evidence was provided that SP-D may have a role in the protection against nonbacterial microorganisms and viruses. In a patient suffering from human immunodeficiency virus (HIV), abnormalities were found in the pulmonary surfactant. The development of *Pneumocystis carinii* enhances these abnormalities [78]. During *P. carinii* pneumonia, SP-D accumulates in the lung [191], interacts with gpA (the major surface antigen of *P. carinii*), and augments the binding of *P. carinii* to alveolar macrophages [227]. SP-D interacts with the mannose-rich antigen gp120, which modulates an interaction with the alveolar macrophages. In this way SP-D acts as an opsonin. SP-D may also protect against viruses such as influenza A by binding to the virus, and SP-D is even ten times more effective in inhibiting hemagglutination [115].

Phosphatidylinositol Binding

A striking finding is that SP-D can bind PI in a calcium-dependent way [228, 252]. In fact, this is the only known interaction of this surfactant protein and phospholipids. The importance of the interaction between this acidic phospholipid and SP-D regarding homeostasis and metabolism is not clear. Only about 3% of the phospholipids in pulmonary surfactant is PI. Studies done with chimeras of SP-A and SP-D identify the CRDs as essential for interaction with phospholipids [230]. The physiologic significance of binding to PI remains a mystery, but it is conceivable that SP-D may play a role in intracellular lipid sorting or signal transduction.

Hydrophobic Surfactant Proteins

Phizackerley and co-workers were the first to describe the presence of hydrophobic surfactant proteins [253]. Two hydrophobic surfactant proteins are known: SP-B and SP-C. These proteins are soluble in organic solvents such as chloroform/methanol or acetonitrile/water mixtures [247]. Both proteins are secreted by the alveolar type II cells and require specialized intracellular processing events to produce their mature forms [22, 23, 335, 336] because of the extremely hydrophobic nature of these proteins.

Structure of SP-B

SP-B is a small hydrophobic protein of 79 amino acid residues (Fig. 4), known for its high cysteine content [56]. In the species for which the sequence has been described, the primary structure (and especially the positions of the cysteine residues) is conserved (±80% of the mature protein). The cysteine residues form a unique disulfide pattern of three intramolecular bonds and one intermolecular disulfide bond, which stabilize the
protein and produce a dimeric form of SP-B [149, 152]. Mature SP-B contains a small disulfide loop within a larger loop. The secondary structure of SP-B is mainly $\alpha$-helical [32, 215, 322]. The helices have an amphipathic character.

Properties of SP-B

*Promotion of Phospholipid Insertion into the Air-Liquid Interface*

Definitely the most important property of SP-B is to enhance the biophysical properties of surfactant lipids (Table 3). A rapid insertion of phospholipids into the air-liquid interface is obligatory for the maintenance of alveoli integrity. SP-B greatly enhances the formation of a stable surface film by inducing the insertion of phospholipids into the monolayer [121, 174, 233, 234]. The positive charges of the protein are essential for the activity of the protein [43], and the interaction with (negatively charged) PG enhances phospholipid adsorption [34, 355, 356]. During expiration, the surface area is decreased, and hence the surface pressure in the monolayer is increased. Experiments with positively charged peptides resembling fragments of SP-B showed an increase of collapse pressure of palmitic acid up to 70 mN/m [195]. At a surface pressure higher than 40–45 mN/m, SP-B is squeezed out of the monolayer, together with two or three phospholipid molecules per SP-B dimer [304]. Later, during expansion, a new cycle is started by SP-B-catalyzed insertion of phospholipids into the monolayer [165]. During this process part of SP-B may be degraded as was shown in vitro by continuous alteration of the surface area [325].

In vivo experiments in preterm rabbits [265] and selective blocking of SP-B [267] did confirm the significance of this protein. Recently, Nogee and co-workers described a frame shift mutation in the SP-B cDNA [223], which resulted in children unable to produce SP-B. They were suffering from severe respiratory failure, eventually leading to death [222].
Formation of Tubular Myelin

SP-B is, together with SP-A, necessary for the formation of tubular myelin structures [259, 301, 347]. SP-B is able to induce the calcium-dependent fusion of membranes [236, 259]. In SP-B-deficiency an abundance of alveolar concentric multilamellar structures is found, but no tubular myelin [60]. It is hypothesized that SP-B induces the formation of contact sites between bilayers in tubular myelin which enable flow of lipids from the outer leaflet of a bilayer to the adjacent bilayer (or monolayer).

The activity of surfactant in lowering the surface tension is reduced by serum proteins. Surfactant inactivation by serum is reduced by synthetically produced SP-B [5]. This may be explained by the fact that lipids in large membrane structures, like tubular myelin, are more protected from exogenous factors that could impair surface activity.

Molecular Ordering of the Phospholipid Layer

The addition of SP-B increases the inter- and intramolecular ordering of bilayer membranes [43, 330], especially under the gel to fluid phase transition temperature. This ordering is possibly the result of a specific interaction of the positively charged SP-B with the PG headgroup [12, 330, 356]. One monomeric SP-B molecule influences 50–70 molecules of phospholipid [286]. It has been suggested that SP-B reduces the surface tension by an increase of the lateral stability of the phospholipid layer [43]. In contrast, Vincent and co-workers found that synthetic peptide fragments, which resemble SP-B, increase the lipid disorder. Dynamic bilayer microheterogeneities caused by the interactions of SP-B and PG may be essential for pulmonary mechanics [331, 356]. For more information regarding protein-lipid interactions and biophysical properties of surfactant the reader is referred to other review articles [100, 165].

Structure of SP-C

The second member of the group of hydrophobic surfactant proteins is SP-C (Fig. 5). The unique properties and metabolism of this protein have recently been reviewed [24]. This small protein of only 35 amino acid residues is only soluble in organic compounds such as chloroform or 80% acetonitrile in water [247]. The protein is extremely hydrophobic, and is characterized by a high content of valine residues. Two thirds of the protein consists of a continuous hydrophobic stretch, and the secondary structure of this part of the protein is a regular α-helix [154, 244, 286] which is able to span a DPPC bilayer [216]. It has been shown that the long axis of the α-helix is oriented parallel to
the lipid acyl chains [323]. Palmitoylation of the two cysteine residues adds to the hydrophobic character of the protein [57]. Canine SP-C contains only one (palmitoylated) cysteine residue [153]. The palmitoyl chains are linked to the cysteines with a thioester [296]. The function of the acylation is not clear, but it is speculated that palmitoylation leads to a better binding of a protein to a membrane [50, 197], influences the conformation and orientation of peptides [161], or plays a role in membrane fusion [220]. Positively charged lysine and arginine residues are found at positions 11 and 12, respectively. These positive charges are important for the binding of the protein to negatively charged phospholipids [49]. Both monomeric and dimeric forms of SP-C are found, but the function of the two forms remains to be clarified. Dimeric proteins form structures that may have dynamic properties that are different from single chain surfactants [158]. In bovine SP-C, the dimeric form appears to have a secondary structure that is almost exclusively β-sheet [13]. However, the dimeric form of canine SP-C is mainly α-helical [51]. Recently, it was shown that the secondary structure of SP-C depends on the solvent in which the protein is dissolved. When SP-C is allowed to form protein-protein interactions, mainly β-sheet is formed [54]. SP-C gradually self-associates when present in a mixture resembling pulmonary surfactant, even at a temperature below 38°C [135]. In the species analyzed (rat [82], human, porcine [57, 151] a marked conservation in primary structure of SP-C exists, which implies a strong evolutionary pressure [117].

Properties of SP-C

Promotion of Phospholipid Insertion into the Air-Liquid Monolayer

SP-C is able to stimulate insertion of phospholipids out of a subphase into the air-liquid interface in a calcium-dependent way (Table 4) [233, 302]. This process is preceded by the SP-C-dependent binding of phospholipid vesicles to the monolayer [234]. It is likely that SP-C is present in the monolayer but at high pressures (higher than 55
mN/m) SP-C is squeezed out [166]. When SP-C is squeezed out, eight to ten PC molecules/molecule of SP-C accompany the protein. This raises the possibility for SP-C to modify the composition of the monolayer [305].

Ordering of Phospholipids

In mixtures of SP-C and phospholipids, the protein alters the arrangement of the lipid bilayers [347] and the packing of phospholipids in monolayers [248]. One SP-C molecule binds 20–35 lipid molecules [286, 289]. Incorporation of SP-C into a phospholipid bilayer increases the phospholipid ordering parameter, and thereby it may increase the lateral pressure within the bilayer [136]. SP-C causes an increase in the limiting anisotropy in both the gel and liquid crystal phases [75]. In contrast, SP-C appears to disrupt the lipid structure in its immediate vicinity, whereas SP-B lacks this quality [137]. SP-C (and cholesterol) can increase the miscibility of PC and PG mixtures [290]. SP-C is not able to induce lipid mixing of vesicles, unless (part of) the vesicles lacks anionic lipids [236]. Interestingly, SP-C, which lacks most of its positively charged residues, is able to induce lipid mixing of vesicles even in the presence of negatively charged lipids [49].

The presence of serum proteins reduces surfactant activity. Surfactant proteins, especially SP-C, may be a target of serum proteins [281]. It was discussed previously that SP-A and SP-B could protect surfactant inactivation to a certain extent. Excess SP-C may also prevent surfactant inactivation. The negative effect of serum constituents on surfactant activity could be reduced by (synthetically) produced SP-C in the presence of calcium [5, 6]. In a preliminary study, it has been reported that SP-C is capable—in the presence of calcium ions—of enhancing the lipid aggregation caused by SP-A [36]. Protein-protein interactions in surfactant have not been studied extensively, although these interactions may turn out to be essential for proper surfactant function.

Disorders of Surfactant

Surfactant consists of a complex mixture that is impaired in several diseases. This was noticed for the first time by Avery and Mead, who described that a shortage of surface active material leads to a higher surface tension at the air-liquid interface in the lungs in neonatal RDS [10]. Measurement of pulmonary compliance and the gestational age generates the highest accuracy in predicting the appearance of RDS [28, 288]. The main cause of RDS is a shortage of surfactant, and leakage of serum proteins to the alveolar space probably contributes to the disease. Lungs of infants dying from RDS contain all normal components except tubular myelin [58]. As SP-A and SP-B are
essential for the formation of tubular myelin, this could indicate that one or both of these proteins are nonfunctional or missing. This was confirmed by a study showing that neonates seem to have an immature SP-A metabolism [217].

In 1993, a pulmonary SP-B deficiency was described (named congenital alveolar proteinosis), originating from a deficiency of SP-B mRNA [222]. By determination of the sequence of the SP-B transcript in affected children, it was discovered that a frame shift mutation is responsible for this disease [59, 223]. In mice it has been demonstrated that only the animals homozygous for this allele were affected [40]. Interestingly, to date, six different mutations in this gene were identified [345]. The SP-B deficiency is associated with SP-A and SP-C abnormalities. Ultrastructural abnormalities, such as a reduced number of lamellar bodies or the absence of tubular myelin, suggest a significant derangement of surfactant metabolism [59]. The results of the treatment of infants suffering from this disease are still very poor. Up to now, total cardiopulmonary support, involving extracorporeal membrane oxygenation, repeated surfactant instillations, and corticosteroid therapy has not led to successful treatment [114, 345].

A disease probably caused by a complex of factors is adult (or acute) respiratory distress syndrome (ARDS). The potential of endogenous surfactant is diminished by the presence of serum proteins, but a shortage of surfactant may also play a role in this disease. It is shown that the chemical composition and the functional activity of surfactant are changed as a result of ARDS [96].

Alveolar proteinosis is a disease in which the quantity of the alveolar material is increased but in which the composition is changed. Most notably, the content of SP-A is elevated [131, 184], but the ratio of SP-A to protein is approximately the same as in healthy patients. An accumulation of SP-D in the lungs of alveolar proteinosis patients was also reported [52]. In serum of alveolar proteinosis patients SP-A is present as a complex with immunoglobulins [132, 184].

A case report describes two children with recurrent cyanotic periods who had a lower content of surfactant [126]. In children with recurrent ALTE (apparent life-threatening events), definable abnormalities in the physical properties of surfactant have also been described [202]. These findings may provide a sensitive means of identifying those at risk of recurrent ALTE or sudden infant death syndrome (SIDS).

Multiple mechanisms, such as pH change [107] or the presence of LysoPC, can inactivate performed pulmonary surfactant surface films, an effect that is opposed by the hydrophobic surfactant proteins or the addition of calcium ions [5, 6]. The serum proteins are an important cause of the deterioration of the function of surfactant [280, 281]. The presence of fibrinogen is fatal for surfactant activity [279]. Polymerizing fibrin incorporates surfactant; but after lysis of the fibrin clot, the activity of the surfactant is restored [97]. Anesthetics such as halothane [213], toxic agents such as polyurethane smoke [240], or drugs [98] can negatively influence the biosynthesis and function of pulmonary surfactant in vivo and in vitro. An optimal function of surfactant is dependent on a delicate balance of its constituents and is only seen when all constituents are present, and no inhibition is found from exogenous factors.

Several other factors are known which impair surfactant synthesis and function. Among them are oxidant gases (e.g. nitrogen dioxide exposition [208, 218, 219] or ozone exposure [98, 260]), shortage of copper during the gestation period (associated with a lower birth weight and neonatal lung abnormality [2]), or iron-transferrin ac-
cumulation in epithelial lining fluid (promoting the formation of free radicals, which inactivates the surfactant system [113]).

**Therapeutic Effects of Hormones**

The administration of hormones can be used to influence the biosynthesis and function of surfactant. Several factors improve surfactant biosynthesis and function. A deficiency of surfactant can be prevented by maternal administration of glucocorticoids (for a review, see Ref. 221). This therapy results in an increased ventilatory and cardiovascular response [294]. The effect is a decrease of morbidity [159], in spite of a brief period of suppression of the basal corticoid concentration. Postnatal glucocorticoid therapy shows no clear evidence of long term benefits [160]. However, the combined use of corticosteroids with surfactant improved the outcome of therapy compared with the use of surfactant alone [147]. In experimental animals, all four surfactant proteins are increased as a result of the treatment with corticosteroids. In rabbits, it has been shown that corticosteroids (glucocorticoids) cause an increase in SP-B mRNA and a large increase in SP-A mRNA [48, 71, 84]. However, there is a difference between the two proteins in the magnitude of the response, indicating that the expression of SP-A and SP-B may be regulated independently [63, 287]. It has been reported that the regulation of SP-A may be dependent on the dose and the time of exposure [140]. There is also a dexamethasone-induced pre- and postnatal increase of the production of SP-D, an effect that is absent when dexamethasone is administered to adult rats [229]. The extent of regulation of SP-C mRNA is still under debate, varying from no increase [48] to a 35-fold increase of SP-C mRNA compared with a control group [326]. Differential glucocorticoid regulation of both hydrophobic proteins has been reported [77, 326]. There is still discussion regarding by which mechanisms corticosteroids accelerate surfactant lipid synthesis [9, 268, 282].

The administration of corticosteroids is a cause of growth retardation and is a potential risk for the mother. To overcome these problems, alternatives have been investigated. A single dose of betamethasone instead of multiple doses showed a negative response, as there was no lung maturity observed, but still growth retardation of the newborn animals [299]. A second approach is ultrasound-guided single fetal corticosteroid treatment. An intramuscular injection of corticosteroids was the most promising technique to obtain improved postnatal lung function in lambs [148]. The ultrasound-guided, intramuscular injection of thyroxine did not augment the corticosteroid effects [38].

A second factor contributing to the beneficial effects of glucocorticoids is thyrotropin. There are indications that the SP-B gene promoter is a target for thyroid transcription factor 1, thereby regulating the transcription of the SP-B gene [30, 353]. Combined maternal treatment with thyrotropin-releasing hormone and glucocorticoids in preterm lambs increases lung compliance, the total amount of phospholipids, and the saturated PC content in alveolar lavage in preterm lambs [214]. In premature rabbits that had received combined therapy 2 days before birth, no increased surfactant metabolism or mobilization of saturated PC was seen [282]. A randomized, controlled trial of antepartum thyrotropin-releasing hormone and betamethasone indicated a reduction in the incidence of RDS and improved survival of preterm infants [173].
Other potential factors such as retinol [86] or endothelin-1 [283] have been studied in animals, but their therapeutic effect remains to be resolved.

**Therapeutic Use of Surfactant**

Surfactant has had therapeutic use since Fujiwara and co-workers demonstrated its clinical potential in 1980 [87]. A review of pulmonary surfactant therapy was published recently [145]. Convincing evidence has been collected showing that the severity of neonatal RDS can be reduced by replacement of surfactant. Surfactant can be used prophylactically or given to infants who have developed the disease. Treatment of infants with RDS with isolated surfactant or with synthetic surfactant has a beneficial effect on the alveolar ventilation [272] and results in a rapid increase of the arterial oxygen tension [87, 144, 226, 266]. It also increases lung volume and respiratory mechanics as a result of the opening of new distal airways [329]. Surfactant therapy leads to improved aeration, suggesting an end-expiratory increased volume of air [211]. The overall effect is a significantly improved survival rate [194, 204, 209].

There has been discussion as to whether surfactant should be given prophylactically or as rescue therapy. It has been reported that prophylactic administration of surfactant is more effective than early treatment of RDS (rescue therapy), especially in infants under 28 weeks gestation and in infants weighing less than 1,000 g [72, 164]. Less ventilation is required, and lower mortality is seen in this group [163, 238]. Despite these reports in favor of the prophylactic use of surfactant, rescue therapy is normally used. Its advantages are less oxygen dependence and less use of surfactant (and hence, lower cost) [145, 204]. It is not yet established whether neurologic differences are induced in infants who received surfactant therapy vs infants who did not. In a follow-up investigation, no difference in neurologic outcome was found between the surfactant-treated and the control groups [80]. In contrast, it was reported that infants who received surfactant had lower mean mental and motor scores. This would favor giving replacement therapy only to children with postnatal evidence for RDS [324]. Treatment with surfactant consists of one or two doses. There are no indications that a third or fourth dose would be useful [238]. When comparing the different surfactant preparations, there are only small differences in the rate of mortality or bronchopulmonary dysplasia [55, 133]. The best regime for the treatment of RDS is still under investigation [27, 62, 70, 110, 256, 291, 292, 358]. However, despite all efforts, a group of infants (up to 30%) remains which does not respond to surfactant treatment [79].

After prolonged ventilation of the immature lung, destruction of lung parenchyma can be seen. This is mainly a result of barotrauma [28]. Surfactant is given to improve lung function, but surfactant therapy has also proven to have a positive effect on the structure of the lung. Surfactant replacement results in maintenance of more normal parenchyma with less atelectasis during prolonged ventilation of the immature lung. No effect is seen on the alveolar type II cells after surfactant treatment [255, 256], and the therapy is beneficial for long term resistive air flow properties [1]. Children who received surfactant showed less wheezing when they were 24 months old compared with children who did not receive surfactant [300]. Nowadays, the effects of surfactant treatment of premature infants are considerable. Mortality and morbidity of the preterm
neonates are significantly reduced as an effect of surfactant therapy [204, 242]. Eighty percent of the decline of United States infant mortality rate between 1989 and 1990 could be attributed solely to the use of surfactant. Morbidity also was reduced; leading to lower costs in the American health care [278]. In some populations, the limit of viability is now decreased to 23–25 weeks gestation [4, 80], and the mortality of children weighing 600–1,300 g at birth is decreased by approximately 20% [134].

Surfactant treatment could still be optimized. Several techniques are under investigation: antepartum addition of a combination of thyrotropin-releasing hormone and betamethasone [173], addition of antithrombin III to surfactant (to form a complex with thrombin, thereby neutralizing its effect) [274], dilution of surfactant with a saline solution to obtain a better distribution [312], supplementation with inositol in premature infants to increase survival and decrease retinopathy [111], or a combined treatment of a single dose of surfactant and nasal continuous positive airway pressure [328].

A second disease for which administration of synthetic surfactant could be useful is ARDS [8, 95]. (For a review, see Ref. 188.) To study ARDS in an animal model, several procedures have been developed. One example is aspiration of hydrochloric acid in the lungs, which results in reduced gas exchange. The acid causes damage to the alveolar septa, resulting in alveolar edema, a damaged surfactant system, and an inhibition of the surfactant because of the proteins in the edema fluid. Administration of surfactant as soon as possible after the aspiration prevents reduced gas exchange [73]. Bronchoalveolar lavage prior to the surfactant instillation is even more effective [74]. In animal modes of ARDS, lung surfactant improves gas exchange [108]. In small studies the effectiveness of surfactant in ARDS treatment has been studied [116, 122, 143, 293]. The application of surfactant alone will probably not be enough to treat patients suffering from ARDS, and additional therapy will be necessary. The potential therapeutic benefit of the addition of pentoxifylline has been studied to see whether this addition prevents intraalveolar fibrosis in ARDS [180]. As most studies are not complete, and ARDS has multiple causes, it is difficult to predict the place of surfactant in the treatment of this disease.

A third disease in which surfactant therapy promises to be a potential tool is meconium aspiration [298]. In a rat model, meconium aspiration induced diffuse and prominent atelectasis, intraalveolar edema, and hyaline membranes. These morphologic abnormalities were reversed by a high dose regimen of exogenous surfactant [299]. However, in a piglet model, no improvement in oxygenation, surface tension, or lung histology was observed after surfactant therapy, combined with high frequency jet ventilation [332]. Surfactant therapy in full term infants with respiratory failure due to meconium aspiration was often effective in improving gas exchange. A randomized controlled trial of surfactant therapy for this indication has to be performed [167].

There are several other diseases or situations in which the composition or the quality of surfactant is affected. The rationale for surfactant treatment has to be investigated for each of these diseases (Table 5).

The use of surfactant is relatively simple and successful. So far no specific immunologic response to the proteins present in surfactant has been discovered [14, 295, 344]. Administration can be done by instillation or by nebulization. Nebulization of surfactant gives a better distribution [186, 187, 189, 309], but the alveolar recovery of exogenous surfactant was better when instillation was performed [188]. The response
to a surfactant is determined by both the surfactant composition and the ventilation strategy [231]. The activity of surfactant is improved when hydrophobic surfactant proteins are constituents of the surfactant [109], whereas positive end-expiratory pressure (PEEP) improved the response to supplied surfactant [265, 277, 284]. The application of high frequency oscillatory ventilation may be useful for the prevention of lung injury (especially air leak syndrome) [125, 142, 203] and does not alter the turnover of surfactant [340]. In animal experiments it has been demonstrated that intraamniotic surfactant is taken up from the amniotic fluid [89]. A single treatment with surfactant in utero significantly improved the clinical course but did not completely prevent hyaline membrane disease [88].

The serum proteins present in the affected lung can inactivate the administered surfactant, especially in the presence of lysophosphatidylcholine [45]. Surfactant inactivation can be reduced by SP-B and SP-C [7, 327], by SP-A [47, 357], or by palmitic acid [44]. In a study in which surfactant is instilled into the lungs of preterm lambs and recovered after 5 h of ventilation, it has been shown that the newly recovered surfactant is more active than the original exogenous surfactant preparation [141]. Exogenous surfactant probably associates with components of the endogenous surfactant. This indicates that the clinical efficacy of the surfactant preparation is not optimal, and that the biologic system adds properties to the surfactant which may be important [129].

Complications in Surfactant Therapy

With the increased use of surfactant, negative effects have been observed. In infants, cerebral perfusion was affected during and at 10 min after surfactant instillation [310]. Despite increased pulmonary function, a short decrease in cerebral activity is observed after surfactant treatment [123]. A comparison of the hemodynamics of preterm neonates with RDS suggests that rapid instillation of surfactant leads to a uniform distribution in the lungs. This may be the reason for an increase in cerebral blood flow [271,
It has been shown that prenatal dexamethasone treatment combined with exogenous surfactant therapy has some benefits over the standard therapy; it decreases cerebral complications [159].

A serious problem is that pulmonary complications such as pulmonary hemorrhage are associated with the use of exogenous surfactant [261]. Prenatal dexamethasone treatment combined with exogenous surfactant therapy decreases pulmonary morbidity [159]. Also, the use of high frequency oscillatory ventilation in infants with severe RDS improves oxygenation and reduces the occurrence of an air leak syndrome [125].

A third problem is represented by left-to-right shunting, which appears to be a common event following surfactant treatment [310]. Synthetic surfactant replacement in infants with RDS reduces pulmonary vascular resistance, resulting in a significant but transitory reduction in pulmonary arterial pressure and an increase in ductal flow velocity [155, 156]. The mean arterial blood pressure is decreased by 9.3 mmHg after surfactant adjustment [123]. Recently, it has been described that therapeutic pulmonary surfactant may be associated with in vitro lysis of red blood cells. This cytotoxicity differs for different surfactants and different dosages [81]. In vitro, it has been demonstrated that synthetic surfactants can act as an antioxidant; in vivo, surfactants have been shown to scavenge oxidants to protect against hyperoxic lung injury [85, 91]. The antioxidant function of alveolar surfactant is caused by the presence of lipophilic antioxidantia, such as vitamin E [270]. In a preliminary study in primates, however, porcine surfactant did not protect the lung against oxygen injury [138]. Neither incidence nor intensity of retinopathy was affected by use of prophylactic surfactant therapy [263].

In conclusion, increased knowledge of surfactant will lead to a more optimal composition of the surfactants and a better treatment regime. This will eventually result in a reduced incidence of serious pulmonary and nonpulmonary complications.

References

1. Abbasi S, Bhutani VK, Gerdes JS (1993) Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr 122:446–452
2. Abdel-Mageed AB, Welti R, Ohme FW, Pickrell A (1994) Perinatal hypocuprosis affects synthesis and composition of neonatal lung collagen, elastin and surfactant. Am J Physiol 267:L679–L685
3. Adachi H, Hayashi H, Sato H, Dempo K, Akino T (1989) Characterization of phospholipids accumulated in pulmonary-surfactant compartments of rats intratracheally exposed to silica. Biochem J 262:781–786
4. Allen MC, Donahue PK, Dusman AE (1993) The limit of viability-neonatal outcome of infants born at 22 to 25 weeks' gestation. N Engl J Med 329:1597–1601
5. Amirkhanian JD, Bruni R, Waring AJ, Navar C, Taechus HW (1993) Full length synthetic surfactant proteins, SP-B and SP-C, reduce surfactant inactivation by serum. Biochim Biophys Acta 1168:315–320
6. Amirkhanian JD, Bruni R, Waring AJ, Taechus HW (1991) Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1096:355–360
7. Amirkhanian JD, Taechus HW (1993) Reversible and irreversible inactivation of preformed pulmonary surfactant surface films by changes in subphase constituents. Biochim Biophys Acta 1165:321–326
8. Anderson BM, Jackson F, Moxley MA, Longmore WJ (1992) Effects on experimental acute lung injury 24 hours after exogenous surfactant instillation. Exp Lung Res 18:191–204
9. Ashton MR, Postle AD, Smith DE, Hall MA (1994) Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease. Arch Dis Child 71:F114–F117
10. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97:517–523
11. Baatz JE, Bruno MD, Ciraolo PJ, Glasser SW, Stripp BR, Smyth KL, Korfhagen TR (1994) Utilization of modified surfactant-associated protein B for delivery of DNA to airway cells in culture. Proc Natl Acad Sci USA 91:2547–2551
12. Baatz JE, Elledge B, Whitsett JA (1990) Surfactant protein SP-B induces ordering at the surface of model membrane bilayers. Biochemistry 29:6714–6720
13. Baatz JE, Smyth KL, Whitsett JA, Baxter C, Absolom DR (1992) Structure and functions of a dimeric form of surfactant protein C: a Fourier transform infrared and surfactometry study. Chem Phys Lipids 63:91–104
14. Bombar Oetomo S, Bos AF, de Lei L, Okken A, van Donderen L, Halliday HL, Walti H (1993) Immune response after surfactant treatment of newborn infants with respiratory distress syndrome. Biol Neonate 64:341–345
15. Bangham AD (1992) Surface tension in the lungs. Nature 359:110
16. Bangham AD (1995) Surface tensions in the lung. Biophys J 68:1630–1631
17. Baritussio A, Alberti A, Quagliino D, Pettenazzo A, Dalzoppo D, Sartori L, Pasquali-Ronchetti I (1994) SP-A, SP-B, and SP-C in surfactant subtypes around birth: reexamination of alveolar life cycle of surfactant. Am J Physiol 266:L436–L447
18. Bastacky J, Goerke J, Lee CY, Yager D, Kenaga L, Koushafer H, Hayes TL, Chen Y, Clements JA (1993) Alveolar lining liquid layer is thin and continuous: low-temperature scanning electron microscopy of normal rat lung. Am Rev Respir Dis 147:147 (abstr)
19. Batenburg JJ (1992) Surfactant phospholipids: synthesis and storage. Am J Physiol 262:L367–L385
20. Bates SR, Dodia C, Fisher AB (1994) Surfactant protein A regulates uptake of pulmonary surfactant by lung type II cells in microporous membranes. Am J Physiol 267:L753–L760
21. Baybutt RC, Smith JE, Yeh Y-Y (1993) The effect of dietary fish oil on alveolar type II cell fatty acids and lung surfactant phospholipids. Lipids 28:167–172
22. Beers MF, Kim CY, Dodia C, Fisher AB (1994) Localization, synthesis, and processing of surfactant protein SP-C in rat lung analyzed by epitope-specific antipeptide antibodies. J Biol Chem 269:20318–20328
23. Beers MF, Lomax C (1995) Synthesis and processing of hydrophobic surfactant protein C by isolated rat type II cells. Am J Physiol 269:L744–L753
24. Beers MF, Wali A, Eckenhoff MJ, Feinstein SI, Fisher JH, Fisher AB (1992) An antibody with specificity for surfactant protein C precursors: identification of pro-SP-C in rat lung. Am J Respir Cell Mol Biol 7:368–378
25. Benne CA, Kraaijeveld CA, van Strijp JAG, Brouwer E, Harmsen M, Verhoef J, van Golde LMG, van Iwaarden JF (1995) Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J Infect Dis 171:335–341
26. Benson B, Hawgood S, Schilling J, Clements J, Damm D, Cordell B, White RT (1985) Structure of canine pulmonary surfactant apoprotein: cDNA and complete amino acid sequence. Proc Natl Acad Sci USA 82:6379–6383
27. Berry DD, Pramanik AK, Philips JB, Buchter DS, Kanarek KS, Easa D, Kopelman AE, Edwards K, Long W, American Exosurf Neonatal Study Group II (1994) Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing ≥1250 grams with respiratory distress syndrome. J Pediatr 124:294–301
28. Bhutani VK, Abbasi S (1992) Relative likelihood of bronchopulmonary dysplasia based on pulmonary mechanics measured in preterm neonates during the first week of life. J Pediatr 120:605–613
29. Boggaram V, Qing K, Mendelson CR (1988) The major apoprotein of rabbit pulmonary surfactant: elucidation of primary sequence and cyclic AMP and developmental regulation. J Biol Chem 263:2939–2947
30. Bohinski RJ, di Lauro R, Whitsett JA (1994) The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 14:5671–5681
31. Bos AP, Tibboel D, Hazebroek FWJ, Molenaar JC, Lachmann B, Gommers D (1991) Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 338:1279
32. Bruni R, Taeusch HW, Waring AJ (1991) Surfactant protein B: lipid interactions of synthetic peptides representing the amino-terminal amphipathic domain. Proc Natl Acad Sci USA 88:7451–7455
33. Bui KC, Walther FJ, David-Cu R, Garg M, Warburton D (1992) Phospholipid and surfactant protein A concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation. J Pediatr 121:271–274
34. Camacho L, Cruz A, Castro R, Casals C, Pérez-Gil J (1996) Effect of pH on the interfacial adsorption activity of pulmonary surfactant. Colloids Surfaces B Biointerfaces 5:271–277
35. Casals C, Miguel E, Pérez-Gil J (1993) Tryptophan fluorescence study on the interaction of pulmonary surfactant protein A with phospholipid vesicles. Biochem J 296:583–593
36. Casals C, Ruano MLF, Miguel E, Sanchez P, Pérez-Gil J (1994) Surfactant protein-C enhances lipid aggregation activity of surfactant protein-A. Biochem Soc Trans 22:370S
37. Chander A, Fisher AB (1990) Regulation of lung surfactant secretion. Am J Physiol 258:L241–L253
38. Chen C-M, Ikegami M, Ueda T, Polk DH, Jobe AH (1995) Fetal corticosteroid and G4 treatment effects on lung function of surfactant-treated preterm lambs. Am J Respir Crit Care Med. 151:21–26
39. Chung J, Yu S-H, Whitsett JA, Harding PGR, Possmayer F (1989) Effect of surfactant-associated protein-A (SP-A) on the activity of lipid extract surfactant. Biochim Biophys Acta 1002:348–358
40. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE, Whitsett JA (1995) Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 92:7794–7798
41. Clements JA (1957) Surface tension of lung extracts. Proc Soc Exp Biol Med 95:170–172
42. Clements JA, Brown ES, Johnson RP (1958) Pulmonary surface tension and the mucus lining of the lungs: some theoretical considerations. J Appl Physiol 12:262–268
43. Cochrane CG, Revak SD (1991) Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 254:566–568
44. Cockshutt AM, Absolom DR, Possmayer F (1991) The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins. Biochim Biophys Acta 1085:248–256
45. Cockshutt AM, Possmayer F (1991) Lyposphosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta 1086:63–71
46. Cockshutt AM, Possmayer F (1992) Metabolism of surfactant lipids and proteins in the developing lung. In: Robertson B, van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: From Molecular Biology to Clinical Practice. Elsevier Science Publishers, Amsterdam, pp 339–378
47. Cockshutt AM, Weitz J, Possmayer F (1990) Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 29:8424–8429
48. Connelly IH, Hammond GL, Harding PG, Possmayer F (1991) Levels of surfactant-associated protein messenger ribonucleic acids in rabbit lung during perinatal development and after hormonal treatment. Endocrinology 129:2583–2591
49. Creuwels LAJM, Boer EH, Demel RA, van Golde LMG, Haagsman HP (1995) Neutralization of the positive charges of surfactant protein C: Effects on structure and function. J Biol Chem 270:16225–16229
50. Creuwels LAJM, Demel RA, van Golde LMG, Benson BJ, Haagsman HP (1993) Effect of acylation on structure and function of surfactant protein C at the air-liquid interface. J Biol Chem 268:26752–26758
51. Creuwels LAJM, Demel RA, van Golde LMG, Haagsman HP (1995) Characterization of a dimeric canine form of surfactant protein C (SP-C). Biochim Biophys Acta 1254:326–332
52. Crouch E, Persson A, Chang D (1993) Accumulation of surfactant protein D in human pulmonary alveolar proteinosis. Am J Pathol 142:241–248
53. Crouch E, Persson A, Chang D, Heuser J (1994) Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem 269:17311–17319
54. Cruz A, Casals C, Pérez-Gil J (1995) Conformational flexibility of pulmonary surfactant protein SP-B and SP-C, studied in aqueous organic solvents. Biochim Biophys Acta 1255:68–76
55. Cummings JJ, D’Eugenio DB, Gross SJ (1989) A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 320:1505–1510

56. Curstedt T, Johansson J, Barros-Söderling J, Robertson B, Nilsson G, Westberg M, Jörnvall H (1988) Low molecular-mass surfactant protein type I: the primary structure of a hydrophobic 8-kDa polypeptide with eight half-cystine residues. Eur J Biochem 172:521–525

57. Curstedt T, Johansson J, Persson P, Eklund A, Robertson B, Löwenadler B, Jörnvall H (1990) Hydrophobic surfactant-associated polypeptides: SP-C is a lipopeptide with two palmitoylated cysteine residues, whereas SP-B lacks covalently linked fatty acyl groups. Proc Natl Acad Sci USA 87:2985–2989

58. de Mello DE, Heyman S, Phelps DS, Floros J (1993) Immunogold localization of SP-A in lungs of infants dying from respiratory distress syndrome. Am J Pathol 142:1631–1640

59. de Mello DE, Heyman S, Phelps DS, Hamvas A, Nogee L, Cole S, Colten HR (1994) Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 11:230–239

60. de Mello DE, Nogee LM, Heyman S, Krous HF, Hussain M, Merritt TA, Hsuek W, Haas JE, Heidelberger K, Schumacher R, Colten HR (1994) Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 125:43–50

61. De Sanctis GT, Tompiewicz RP, Rubin BK, Schürch S, King M (1994) Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 7:1616–1621

62. de Winter JP, Merth IT, van Bel F, Egberts J, Brand R, Quanjer PH (1994) Changes of respiratory system mechanics in ventilated lungs of preterm infants with two different schedules of surfactant treatment. Pediatr Res 35:541–549

63. Dekowski SA, Snyder JM (1995) The combined effects of insulin and cortisol on surfactant protein mRNA levels. Pediatr Res 38:513–521

64. de Campo JL, Bertranon EG, De Lorenzi A, Hager AA (1994) Nebulised exogenous natural surfactant after cardiac surgery. Lancet 343:8895

65. Dobbs LG, Wright JR, Hawgood S, Gonzalez R, Venstrom K, Nellenbogen J (1987) Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells. Proc Natl Acad Sci USA 84:1010–1014

66. Doyle IR, Jones ME, Barr HA, Orgilge SE, Crockett AJ, McDonald CF, Nicholas TE (1994) Composition of human pulmonary surfactant varies with exercise and level of fitness. Am J Respir Crit Care Med 149:1619–1627

67. Drickamer K (1988) Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 263:9557–9560

68. Drickamer K, Dordal MS, Reynolds L (1986) Mannose-binding proteins isolated from rat liver contain carbohydrate-recognition domains linked to collagenous tails. J Biol Chem 261:6878–6887

69. Drickamer K, Taylor ME (1993) Biology of animal lectins. Annu Rev Cell Biol 9:237–264

70. Dunn MS (1994) Surfactant replacement therapy: prophylaxis or treatment. Pediatrics 92:148–150

71. Durham PL, Wohlford-Lenane CL, Snyder JM (1993) Glucocorticoid regulation of surfactant-associated proteins in rabbit fetal lung in vivo. Anat Rec 237:365–377

72. Egberts J, de Winter JP, Sedin G, de Kleine MJK, Broberger U, van Bel F, Curstedt T, Robertson B (1993) Comparison of prophylaxis and rescue therapy with Curosurf in neonates less than 30 weeks’ gestation: a randomized trial. Pediatrics 92:768–774

73. Eijking EP, Gommers D, So KL, de Maat MPM, Mouton JW, Lachmann B (1993) Prevention of respiratory failure after hydrochloric acid aspiration by intratracheal surfactant instillation in rats. Anesth Analg 76:472–477

74. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B (1993) Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 78:1145–1151

75. Erasmus ME, Petersen AH, Hofstede G, Haagsman HP, Bambang Oetomo S, Prop J (1996) Surfactant treatment before reperfusion improves the immediate function of lung transplanted in rats. Am J Respir Crit Care Med 153:665–670

76. Ertey R, Venkatesh VC, Ballard PL (1993) Glucocorticoids regulate transcription of the genes for surfactant proteins B and C. Am Rev Respir Dis 147:A728 (abstr)
78. Escamilla R, Prevost M-C, Hermant C, Caratero A, Cariven C, Krempf M (1992) Surfactant analysis during *Pneumocystis carinii* pneumonia in HIV-infected patients. Chest 101:1558–1562
79. Fan BR, Jones B, David-Cu R, Bruni R, Taechus HW (1993) Inactivation of surfactants in rat lungs. Am Rev Respir Dis 147:A991 (abstr)
80. Ferrara TB, Hoekstra RE, Couser RJ, Gaziano EP, Calvin SE, Payne NR, Fangman JJ (1994) Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr 124:119–124
81. Findlay RD, Taechus HW, David-Cu R, Walther FJ (1995) Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatr Res 37:26–30
82. Fisher HF, Shannon JM, Hofmann T, Mason RJ (1989) Nucleotide and deduced amino acid sequence of the hydrophobic surfactant protein SP-C from rat: expression in alveolar type II cells and homology with SP-C from other species. Biochim Biophys Acta 995:225–230
83. Fisher JH, Mason R (1995) Expression of pulmonary surfactant protein D in rat gastric mucosa. Am J Respir Cell Mol Biol 12:13–18
84. Fisher JH, McCormack F, Park SS, Stelzner T, Shannon JM, Hofmann T (1991) In vivo regulation of surfactant proteins by glucocorticoids. Am J Respir Cell Mol Biol 5:63–70
85. Fracica PJ, Caminiti SP, Piantadosi CA, DuValongsod FG, Crapo JD, Young SL (1994) Natural surfactant and hyperoxic lung injury in primates. J Appl Physiol 76:1002–1010
86. Fracica PJ, Caminiti SP, Piantadosi CA, DuValongsod FG, Crapo JD, Young SL (1994) Natural surfactant and hyperoxic lung injury in primates. 2. Morphometric analyses. J Appl Physiol 76:1002–1010
87. Fujiwara T, Maeta H, Chida S, Morita T, Wataba Y, Abe T (1980) Artificial surfactant therapy in hyaline membrane disease. Lancet 1:55–59
88. Galan HL, Cipriani C, Coalson JJ, Bean JD, Collier G, Kuehl TJ (1993) Surfactant replacement therapy in utero for prevention of hyaline membrane disease in the preterm baboon. Am J Obstet Gynecol 169:817–824
89. Galan HL, Kuehl TJ (1992) Effect of intra-amniotic administration of exsuf in preterm rabbit fetuses. Obstet Gynecol 80:604–608
90. Geertsma MF, Nibbering PH, Haagsman HP, Daha MR, van Furth R (1994) Binding of surfactant protein A to C1q receptors mediates phagocytosis of *Staphylococcus aureus* by monocytes. Am J Physiol 267:L578–L584
91. Ghio AJ, Fracica PJ, Young SL, Piantadosi CA (1994) Synthetic surfactant scavenges oxidants and protects against hyperoxic lung injury. J Appl Physiol 77:1217–1223
92. Gluck L, Kulovich MV, Borer RC, Brenner PH, Anderson GG, Spellacy WN (1971) Diagnosis of the respiratory distress syndrome by amniocentesis. Am J Obstet Gynecol 109:440–445
93. Gluck L, Motoyama EK, Smits HL, Kulovich MV (1967) The biochemical development of surface activity in mammalian lung. I. The surface-active phospholipids; the separation and distribution of surface-active lecithin in the lung of the developing rabbit fetus. Pediatr Res 1:237–246
94. Goerke J (1974) Lung surfactant. Biochim Biophys Acta 344:241–261
95. Gregory GA, Phibbs RH (1993) Surfactant replacement for respiratory failure: lessons from the neonate. Anesth Analg 76:465–466
96. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA, Hudson LD, Mauder RJ, Crim C, Hyers TM (1991) Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 88:1976–1986
97. Günther A, Kalinowski M, Elssner A, Seeger W (1994) Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity. Am J Physiol 267:L618–L624
98. Haagsman HP (1992) Toxicological aspects of the surfactant system: pulmonary surfactant. In: Robertson B, van Golde LMG, Batenburg JJ (eds) Pulmonary Surfactant: From Molecular Biology to Clinical Practice. Elsevier Science Publishers, Amsterdam, pp 705–734
99. Haagsman HP (1994) Surfactant proteins A and D. Biochem Soc Trans 22:100–106
100. Haagsman HP, Batenburg JJ (1992) Toxicological aspects of the surfactant system: pulmonary surfactant. In: Robertson B, van Golde LMG, Batenburg JJ (eds) Pulmonary Surfactant: From Molecular Biology to Clinical Practice. Elsevier Science Publishers, Amsterdam, pp 705–734
101. Haagsman HP, Casals C, De Hass C, Van Eijk M, Van Golde LMG, van Iwaarden JF, Voorhout WF (1993) Endocytosis of surfactant A (SP-A) and lipids by type II cells studied by laser flow cytometry. Am J Respir Dis 147:145 (abstr)
102. Haagsman HP, Elfring RH, Van Buel BLM, Voorhout WF (1991) The lung lectin surfactant A aggregates phospholipid vesicles via a novel mechanism. Biochem J 275:273–276
103. Haagsman HP, Hawgood S, Sargeant T, Buckley D, White RT, Drickamer K, Benson B (1987) The major lung surfactant protein, SP 28–36, is a calcium-dependent, carbohydrate-binding protein. J Biol Chem 262:13877–13880
104. Haagsman HP, Sargeant T, Hauschka PV, Benson BJ, Hawgood S, Clements JA (1990) Binding of calcium to SP-A, a surfactant-associated protein. Biochemistry 29:8894–8900
105. Haagsman HP, van Golde LMG (1991) Synthesis and assembly of lung surfactant. Annu Rev Physiol 53:441–464
106. Haagsman HP, White RT, Schilling J, Benson BJ, Golden J, Hawgood S, Clements JA (1989) Studies on the structure of the lung surfactant protein, SP-A. Am J Physiol 257:L421–L429
107. Haddad IY, Holm BA, Hlavaty L, Matalon S (1994) Dependence of surfactant function on extracellular pH: mechanisms and modifications. J Appl Physiol 76:657–662
108. Hafner D, Germann P, Hauschke D (1994) Lung surfactant (LSF) improves gas exchange and histopathology in a model of adult respiratory distress syndrome (ARDS). Am J Respir Critical Care Med 149:126 (abstr)
109. Hall SB, Venkitaraman AR, Whitsett JA, Holm BA, Notter RH (1992) Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 145:24–30
110. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC (1993) Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 69:276–280
111. Hallman M, Arjomaa P, Hoppu K (1987) Inositol supplementation in respiratory distress syndrome: relationship between serum concentration, renal concentration, and lung effluent phospholipids. J Pediatr 110:604–610
112. Hallman M, Feldman B, Gluck L (1975) The absence of phosphatidylglycerol in surfactant. Pediatr Res 9:396 (abstr)
113. Hallman M, Sarnesto A, Bry K (1994) Interaction of transferrin saturated with iron with lung surfactant in respiratory failure. J Appl Physiol 77:757–766
114. Hamvas A, Cole FS, deMello DE, Moxley M, Whitsett JA, Colten HR, Nogee LM (1994) Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 125:356–361
115. Hartshorn KL, Crouch EC, White MR, Eggleton P, Tauber AI, Chang D, Sastry K (1994) Evidence for a protective role of pulmonary surfactant protein D (SP-D) agonist influenza A virus. J Clin Invest 94:311–319
116. Haslam PL, Hughes DA, MacNaughton PD, Baker CS, Evans TW (1994) Surfactant replacement therapy in late-stage adult respiratory distress syndrome. Lancet 343:1009–1011
117. Hatziis D, Deitier G, de Mello DE, Floros J (1994) Human surfactant protein-C: Genetic homogeneity and expression in RDS; comparison with other species. Exp Lung Res 20:57–72
118. Haurum JS, Thiel S, Haagsman HP, Laursen SB, Larsen B, Jensenius JC (1993) Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: mannan-binding protein and conglutinin. Biochem J 293:873–878
119. Hawgood S (1989) Pulmonary surfactant apoproteins: a review of protein and genomic structure. Am J Physiol 257:L13–L22
120. Hawgood S, Benson BJ, Hamilton RL (1985) Effects of a surfactant-associated protein and calcium ions on the structure and surface activity of lung surfactant lipids. Biochemistry 24:184–190
121. Hawgood S, Benson BJ, Schilling J, Damn D, Clements JA, White RT (1987) Nucleotide and amino acid sequences of pulmonary surfactant protein SP 18 and evidence for cooperation between SP 18 and SP 28–36 in surfactant lipid adsorption. Proc Natl Acad Sci USA 84:66–70
122. Heikinheimo M, Hynynen M, Rantaiainen P, Andersson S, Hallman M, Kuukkonen S (1994) Successful treatment of ARDS with two doses of synthetic surfactant. Chest 105:1263–1264
123. Hellstrom-Westas L, Bell AH, Skov L, Greisen G, Svenningsen NW (1992) Cerebroelectrical depression following surfactant treatment in preterm infants. Pediatrics 89:643–647
124. Hetting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B (1994) Experimental neonatal group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits. Pediatr Res 36:784–791
125. HIFO Study Group (1993) Randomized study of high-frequency oscillatory ventilation in infants with severe respiratory distress syndrome. J Pediatr 122:609–619

126. Hills BA, Masters IB, Oduffy JF (1992) Abnormalities of surfactant in children with recurrent cyanotic episodes. Lancet 339:1323–1324

127. Hirako N, Sohma H, Kuroki Y, Akino T (1995) Epitope mapping for monoclonal antibody against human surfactant protein A (SP-A) that alters receptor binding of SP-A and the SP-A-dependent regulation of phospholipid secretion by alveolar type II cells. Biochim Biophys Acta 1257:214–222

128. Hoffman AGD, Lawrence MG, Ognibene FP, Suffredini AF, Lipschik GY, Kovacs JA, Masur H, Shelhamer JH (1992) Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 102:1730–1736

129. Holm BA (1993) Surfactant replacement therapy: new levels of understanding. Am Rev Respir Dis 148:834–836

130. Holmskov U, Malhotra R, Sim RB, Jensenius JC (1994) Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 15:67–74

131. Honda Y, Takahashi H, Shi jubo N, Kuroki Y, Akino T (1993) Surfactant protein A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 103:496–499

132. Hook GER, Gilmore LB, Talley FA (1984) Multilamellated structures from the lungs of patients with pulmonary alveolar proteinosis. Lab Invest 50:711–725

133. Horbar JD (1993) A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 123:757–766

134. Horbar JD, Wright EC, Onstad L, and members of the National Institute of Child Health and Human Development Neonatal Research Network (1993) Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601–1300 grams at birth. Pediatrics 92:191–196

135. Horowitz AD, Baatz JE, Whitsett JA (1993) Lipid effects on aggregation of pulmonary surfactant protein SP-C studied by fluorescence energy transfer. Biochemistry 32:9513–9523

136. Horowitz AD, Elledge B, Whitsett JA, Baatz JE (1992) Effects of lung surfactant proteolipid SP-C on the organization of model membrane lipids: a fluorescence study. Biochim Biophys Acta 1107:44–54

137. Horowitz AD, Whitsett JA (1994) Interactions of surfactant proteins SP-C and SP-B with lipids studied by fluorescence energy transfer. Am J Respir Crit Care Med 149:96 (abstr)

138. Huang YCT, Caminiti SP, Fawcett TA, Moon RE, Fracica PJ, Miller FI, Young SL, Piantadosi CA (1994) Natural surfactant and hyperoxic lung injury in primates. 1. Physiology and biochemistry. J Appl Physiol 76:991–1001

139. Deleted in proof

140. Iannuzzi DM, Ersey R, Ballard PL (1993) Biphasic glucocorticoid regulation of pulmonary SP-A: characterization of inhibitory process. Am J Physiol 264:L236–L244

141. Ikegami M, Ueda T, Absolom D, Baxter C, Rider E, Jobe AH (1993) Changes in exogenous surfactant in ventilated preterm lamb lungs. Am Rev Respir Dis 148:837–844

142. Jackson JC, Truong WE, Standaert TA, Murphy JH, Juul SE, Chi EY, Hildebrandt J, Hodson WA (1994) Reduction in lung injury after combined surfactant and high-frequency ventilation. Am J Respir Crit Care Med 150:534–539

143. Jacobson W, Park GR, Saich T, Holcroft J (1993) Surfactant and adult respiratory distress syndrome. Br J Anaesth 70:522–526

144. Jobe AH (1984) Respiratory distress syndrome: new therapeutic approaches to a complex pathophysiology. Adv Pediatr Chicago 30:93–130

145. Jobe AH (1993) Pulmonary surfactant therapy. N Engl J Med 328:861–868

146. Jobe AH, Ikegami M, Sarton-Miller I, Barajas L (1980) Surfactant metabolism of newborn lamb lungs studied in vivo. J Appl Physiol 49:1091–1098

147. Jobe AH, Mitchell BR, Gunkel JH (1993) Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 168:508–513

148. Jobe AH, Polk D, Ikegami M, Newnham J, Sly P, Kohen R, Kelly R (1993) Lung responses to ultrasound-guided fetal treatments with corticosteroids in preterm lambs. J Appl Physiol 75:2099–2105
149. Johansson J, Curstedt T, Jörnvall H (1991) Surfactant protein B: disulfide bridges, structural properties, and kringle similarities. Biochemistry 30:6917–6921
150. Johansson J, Curstedt T, Robertson B (1994) The proteins of the surfactant system. Eur Respir J 7:372–391
151. Johansson J, Curstedt T, Robertson B, Jörnvall H (1988) Size and structure of the hydrophobic low molecular weight surfactant-associated polypeptide. Biochemistry 27:3544–3547
152. Johansson J, Jörnvall H, Curstedt T (1992) Human surfactant polypeptide SP-B disulfide bridges, C-terminal end, and peptide analysis of the airway form. FEBS Lett 301:165–167
153. Johansson J, Persson P, Löwenadler B, Robertson B, Jörnvall H, Curstedt T (1991) Canine hydrophobic surfactant polypeptide SP-C: a lipopeptide with one thioester-linked palmitoyl group. FEBS Lett 281:119–122
154. Johansson J, Szperski T, Curstedt T, Wüthrich K (1994) The NMR structure of the pulmonary surfactant-associated polypeptide SP-C in an apolar solvent contains a valyl-rich α-helix. Biochemistry 33:6015–6023
155. Kääpä P, Kero P, Saraste M (1992) Synthetic surfactant replacement therapy decreases estimated pulmonary artery pressure in respiratory distress syndrome. Am J Dis Child 146:961–964
156. Kääpä P, Seppänen M, Kero P, Saraste M (1993) Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 123:115–119
157. Kalina M, Blau H, Riklis S, Kravtsov V (1995) Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions. Am J Physiol 268:L144–L151
158. Karabori S, Esshelink K, Hilbers PAJ, Smit B, Karthäuser J, van Os NM, Zana R (1994) Simulating the self-assembly of gemini (dimeric) surfactants. Science 266:254–256
159. Kari MA, Hallman M, Eronen M, Teramo K, Virtanen M, Ikonen RS (1994) Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 93:730–736
160. Kari MA, Raivio KO, Venge P, Hallman M (1994) Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens. Pediatr Res 36:387–393
161. Kato T, Lee S, Ono S, Agawa Y, Aoyagi H, Ohno M, Nishino N (1991) Conformational studies of amphipathic α-helical peptides containing an amino acid with a long alkyl chain and their anchoring to lipid bilayer liposomes. Biochim Biophys Acta 1063:191–196
162. Katsumaru Y, Yang DS-C, Epand RM (1992) Fatty-acid chain tilt angles and directions in dipalmitoyl-phosphatidylcholine bilayers. Biophys J 63:1170–1175
163. Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, Jung AL, King K, Mueller D (1993) Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks gestation. Pediatrics 92:90–98
164. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, Sinkin RA, Bartoletti A, Dweck HS, Horgan MJ, Risemberg H, Phelps DL, Shapiro DL (1991) A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks’ gestation. N Engl J Med 324:865–871
165. Keough KMW (1992) Physical chemistry of pulmonary surfactant in the terminal air spaces. In: Robertson B, van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: from molecular biology to clinical practice. Elsevier Science Publishers, Amsterdam, pp 109–164
166. Keough KMW, Pérez-Gil J, Nag K (1994) Adsorption and monolayer formation of some pulmonary surfactant components visualized by epifluorescence microscopy. Am J Respir Crit Care Med 149:95 (abstr)
167. Khammash H, Perlman M, Wojtulewicz J, Dunn M (1993) Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 92:135–139
168. Kharasch VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery ME, Brain JD (1991) Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 144:909–913
169. Khoo R, Gray ME, Hull WM, Whitsett JA, Stahlman MT (1993) Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J Histochem Cytochem 41:1311–1319
170. King RJ, Clements JA (1972) Surface active materials from dog lung. II. Composition and physiologi-

cal correlations. Am J Physiol 223:715–726

171. King RJ, Klass DJ, Gikas EG, Clements JA (1973) Isolation of apoproteins from canine surface active

material. Am J Physiol 224:788–795

172. Klaus MH, Clements JA, Havel RJ (1961) Composition of surface-active material isolated from beef

lung. Proc Natl Acad Sci USA 47:1858–1859

173. Knight DB, Liggins GC, Wealhall SR (1994) A randomized, controlled trial of antepartum thyrotro-
pin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants.

Am J Obstet Gynecol 171:11–16

174. Kobayashi T, Nitta K, Takahashi R, Kurashima K, Robertson B, Suzuki Y (1991) Activity of pulmo-
nary surfactant after blocking the associated proteins SP-A and SP-B. J Appl Physiol 71:530–536

175. Korfhagen TR, Bruno MD, Glasser SW, Ciriaolo PJ, Whitsett JA, Lattier DL, Wikenheiser KA, Clark

JC (1992) Murine pulmonary surfactant SP-A gene: cloning, sequence, and transcriptional activity. Am

J Physiol 263:L546–L554

176. Kremlev SG, Phelps DS (1994) Surfactant protein A stimulation of inflammatory cytokine and im-

munoglobulin production. Am J Physiol 267:L712–L719

177. Kremlev SG, Umstead TM, Phelps DS (1994) Effects of surfactant protein A and surfactant lipids on

lymphocyte proliferation in vitro. Am J Physiol 267:L357–L364

178. Krombach F, Fiehl E, Burkhardt D, Rienmüller R, König G, Adelmann-Grill BC, Idel H, Rosenbruch

M (1994) Short-term and long-term effects of serial bronchoalveolar lavages in a nonhuman primate

model. Am J Respir Crit Care Med 150:153–158

179. Kuan S-F, Rust K, Crouch E (1992) Interactions of surfactant protein D with bacterial lipopolysac-
charides: surfactant protein D is an *Escherichia coli*-binding protein in bronchoalveolar lavage. J Clin

Invest 90:97–106

180. Kullmann A, Vaillant P, Muller V, Martinet Y, Martinet N (1993) In vitro effects of pentoxifylline on

smooth muscle cell migration and blood monocyte production of chemotactic activity for smooth

muscle cells: potential therapeutic benefit in the adult respiratory distress syndrome. Am J Respir Cell

Mol Biol 8:83–88

181. Kuroki Y, Akino T (1991) Pulmonary surfactant protein A (SP-A) specifically binds dipalmitoyl-

phosphatidylcholine. J Biol Chem 266:3068–3073

182. Kuroki Y, Mason RJ, Voelker DR (1988) Alveolar type II cells express a high-affinity receptor for

pulmonary surfactant protein A. Proc Natl Acad Sci USA 85:5566–5570

183. Kuroki Y, McCormack FX, Ogawara Y, Mason RJ, Voelker DR (1994) Epitope mapping for monoclonal antibodies identifies functional domains of pulmonary surfactant protein A that interact with lipids. J Biol Chem 269:29793–29800

184. Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A (1993) Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 147:723–729

185. Lachmann B, Gomers D (1993) Is it rational to treat pneumonia with exogenous surfactant? Eur

Respir J 6:1427–1428

186. Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D (1991) Nebulized vs. instilled exogenous sur-

factant in an adult lung injury model. J Appl Physiol 71:1270–1276

187. Lewis JF, Ikegami M, Jobe AH, Tabor B (1991) Aerosolized surfactant treatment of preterm lambs. J

Appl Physiol 70:869–876

188. Lewis JF, Jobe AH (1993) Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis

147:218–233

189. Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D (1993) Lung function and surfactant

distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J Appl Physiol 74:1256–1264

190. Lim B-L, Wang J-Y, Holmskov U, Hoppe H-J, Reid KMB (1994) Expression of the carbohydrate

derecognition domain of lung surfactant protein D and demonstration of its binding to lipopolysaccharides of gram-negative bacteria. Biochem Biophys Res Commun 202:1674–1680

191. Limper AH, O’Riordan DM, Vuk-Pavlovic Z, Crouch EC (1994) Accumulation of surfactant protein

D in the lung during *Pneumocystis carinii* pneumonia. J Eukaryot Microbiol 41:S98

192. Liou LS, Sastry R, Hartshorn KL, Lee YM, Okama TB, Tauber AI, Sastry KN (1994) Bovine con-
glutinin (BC) mRNA expressed in liver: cloning and characterization of the BC cDNA reveals strong homology to surfactant protein-D. Gene (Amst) 141:277–281
193. Liu M, Wang L, Li E, Enhorning G (1996) Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea pigs. Clin Exp Allergy 26:270–275
194. Long W, Corbet A, Cotton R, Courtney S, McGuiness G, Walter D, Watts J, Smyth J, Bard H, Chernick V, American Exosurf Neonatal Study Group 1, Canadian Exosurf Neonatal Study Group (1991) A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. N Engl J Med 325:1696–1703
195. Longo ML, Bisagno AM, Zasadzinski JAN, Bruni R, Waring AJ (1993) A function of lung surfactant protein SP-B. Science 261:453–456
196. Lotze A, Knight GR, Martin GR, Bulas DI, Hull WM, O’Donnell RM, Whitsett JA, Short BL (1993) Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 122:261–268
197. Lowry DR, Willumsen BM (1989) New clue to Ras lipid glue. Nature 341:384–385
198. Lu J, Wiedemann H, Holmskov U, Thiel S, Tilp R, Reid KBM (1993) Structural similarity between lung surfactant D and conglutinin: two distinct, C-type lectins containing collagen-like sequences. Eur J Biochem 215:793–799
199. Lu J, Willis AC, Reid KBM (1992) Purification, characterization and cDNA cloning of human lung surfactant protein D. Biochem J 284:795–802
200. Malhotra R, Haurum JS, Thiel S, Sim RB (1994) Binding of human collectins (SP-A and MBP) to influenza virus. Biochem J 304:455–461
201. Mason RJ (1992) Surfactant secretion. In: Robertson B, van Golde LMG, Batenburg JJ (eds) Pulmonary Surfactant: From Molecular Biology to Clinical Practice. Elsevier Science Publishers, Amsterdam, pp 295–312
202. Masters IB, Vance J, Hills BA (1994) Surfactant abnormalities in ALTE and SIDS. Arch Dis Child 71:501–505
203. Matsuoka T, Kawano T, Miyasaka K (1994) Role of high-frequency ventilation in surfactant-depleted lung injury as measured by granulocytes. J Appl Physiol 76:539–544
204. Mauskopf JA, Backhouse ME, Jones D, Wold DE, Mammel M, Guthrie R, Long WA (1995) Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: impact on hospital resource use and charges. J Pediatr 126:94–101
205. McBrien M, Katumba JJ, Mukhtar AI (1993) Artificial surfactant in the treatment of near drowning. Lancet 342:1485–1486
206. McNeely TB, Coonrod JD (1993) Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages. J Infect Dis 167:91–97
207. McNeely TB, Coonrod JD (1994) Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. Ann J Respir Cell Mol Biol 11:114–122
208. Mengel RG, Bernhard W, Barth P, von Wichert P, Müller B (1993) Impaired regulation of surfactant phospholipid metabolism in the isolated rat lung after nitrogen dioxide inhalation. Toxicol Appl Pharmacol 120:216–223
209. Mercier CE, Soll RF (1993) Clinical trials of natural surfactant extract in respiratory distress syndrome. In: Long WA (ed) Clinics in Perinatology. Saunders, Philadelphia, pp. 711–735
210. Mikawa K, Maekawa N, Nishina K, Takao Y, Yaku H, Obara H (1993) Selective intrabronchial instillation of surfactant in a patient with pneumoniae: a preliminary report. Eur Respir J 6:1563–1566
211. Milner AD (1993) How does exogenous surfactant work? Arch Dis Child 68:253–254
212. Miyamura K, Leigh LEA, Lu J, Hopkin J, López Bernal A, Reid KBM (1994) Surfactant protein D binding to alveolar macrophages. Biochem J 300:237–242
213. Molliex S, Crestani B, Dureuil B, Bastin J, Rolland C, Aubier M, Desmonts J-M (1994) Effects of halothane on surfactant biosynthesis by rat alveolar type II cells in primary culture. Anesthesiology 81:668–676
214. Moraga FA, Riquelme RA, López AA, Moya FR, Llanos AJ (1994) Maternal administration of glucocorticoid and thyrotropin-releasing hormone enhances fetal lung maturation in undisturbed preterm lambs. Am J Obstet Gynecol 171:729–734
215. Morrow MR, Pérez-Gil J, Simatos G, Boland C, Stewart J, Absolom D, Sarin V, Keough KMW (1993)
Pulmonary surfactant-associated protein SP-B has little effect on acyl chains in dipalmitoyl phosphatidylcholine dispersions. Biochemistry 32:4397–4402

216. Morrow MR, Taneva S, Simatos GA, Allwood LA, Keough KMW (1993) 2H NMR studies of the effect of pulmonary surfactant SP-C on the 1,2-dipalmitoyl-sn-glycero-3-phosphocholine headgroup: a model for transbilayer peptides in surfactant and biological membranes. Biochemistry 32:11338–11344

217. Moya FR, Montes HF, Thomas VL, Mouzinho AM, Smith JF, Rosenfeld CR (1994) Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome. Am J Respir Crit Care Med 150:1672–1677

218. Müller B, Barth P, von Wichert P (1992) Structural and functional impairment of surfactant protein A after exposure to nitrogen dioxide in rats. Am J Physiol 263:L177–L184

219. Müller B, von Wichert P (1993) Effect of nitrogen dioxide inhalation on surfactant phosphatidylcholine synthesis in rat alveolar type II cells. Biochim Biophys Acta 1170:38–43

220. Naeve CW, Williams D (1990) Fatty acids on the A/Japan/305/57 influenza virus hemagglutinin have a role in membrane fusion. EMBO J 9:3857–3866

221. Ng PC (1993) The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Arch Dis Child 68:330–336

222. Nogee LM, de Mello DE, Colten HR (1993) Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 328:406–410

223. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, de Mello DE, Colten HR (1994) A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 93:1860–1863

224. Novick RJ, Possmayer F, Veldhuizen RAW, Menkis AH, McKenzie FN (1992) Surfactant analysis and replacement therapy: a future tool of the lung transplant surgeon? Ann Thorac Surg 52:1194–1200

225. Novick RJ, Veldhuizen RAW, Possmayer F, Lee J, Sandler D, Lewis JF (1994) Exogenous surfactant therapy in thirty-eight-hour lung graft preservation for transplantation. J Thorac Cardiovasc Surg 108:259–268

226. O'Brodovich H, Hannam V (1993) Exogenous surfactant rapidly increases PaO2 in mature rabbits with lungs that contain large amounts of saline. Am Rev Respir Dis 147:1087–1090

227. O'Riordan DM, Standing JE, Kwon K-Y, Chang D, Crouch EC, Limper AH (1995) Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 95:2699–2710

228. Ogasawara Y, Kuroki Y, Akino T (1992) Pulmonary surfactant protein D specifically binds to phosphatidylinositol. J Biol Chem 267:21244–21249

229. Ogasawara Y, Kuroki Y, Tsuzuki A, Ueda S, Misaki H, Akino T (1991) Pre- and postnatal stimulation of pulmonary surfactant protein D by in vivo dexamethasone treatment of rats. Life Sci 50:1761–1767

230. Ogasawara Y, McCormack FX, Mason RJ, Voelker DR (1994) Chimeras of surfactant proteins A and D identify the carbohydrate recognition domains as essential for phospholipid interaction. J Biol Chem 269:29785–29792

231. Ogawa A, Brown CL, Schlueter MA, Benson BJ, Clements JA, Hawgood S (1994) Lung function, surfactant apoprotein content, and level of PEEP in prematurely delivered rabbits. J Appl Physiol 77:1840–1849

232. Ohashi T, Pinkerton K, Ikegami M, Jobe AH (1994) Changes in alveolar surface area, surfactant protein A, and saturated phosphatidylcholine with postnatal rat lung growth. Pediatr Res 35:685–689

233. Oosterlaken-Dijksterhuis MA, Haagsman HP, van Golde LMG, Demel RA (1991) Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 30:8276–8281

234. Oosterlaken-Dijksterhuis MA, Haagsman HP, von Golde LMG, Demel RA (1991) Characterization of lipid insertion into monomolecular mediated layers by lung surfactant proteins SP-B and SP-C. Biochemistry 30:10965–10971

235. Oosterlaken-Dijksterhuis MA, van Eijk M, van Buel BLM, van Golde LMG, Haagsman HP (1991) Surfactant protein composition of lamellar bodies isolated from rat lung. Biochem J 274:115–119

236. Oosterlaken-Dijksterhuis MA, van Eijk M, van Golde LMG, Haagsman HP (1992) Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C. Biochim Biophys Acta 1110:45–50
237. Orgeig S, Barr HA, Nicholas TE (1995) Effect of hyperpnea on the cholesterol to disaturated phospholipid ratio in alveolar surfactant of rats. Exp Lung Res 21:157–174
238. OSIRIS, The Collaborative Group (1992) Early versus delayed neonatal administration of a synthetic surfactant: the judgment of OSIRIS. Lancet 340:1363–1369
239. Oulton M, Fraser M, Dolphin M, Yoon R, Faulkner G (1986) Quantification of surfactant pool sizes in rabbit lung during perinatal development. J Lipid Res 27:602–612
240. Oulton MR, Janigan DT, MacDonald JMR, Faulkner GT, Scott JE (1994) Effects of smoke inhalation on alveolar surfactant subtypes in mice. Am J Pathol 145:941–950
241. Palombo JD, Lydon EE, Chen P-L, Bistrian BR, Forse RA (1994) Fatty acid composition of lung, macrophage and surfactant phospholipids after short-term enteral feeding with n-3 lipids. Lipids 29:643–649
242. Palta M, Weinstein MR, McGuinness G, Gabbert D, Brady W, Peters E (1994) A population study; mortality and morbidity after availability of surfactant therapy. Arch Pediatr Adolesc Med 148:1295–1301
243. Pandit PB, Dunn MS, Colucci EA (1995) Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 95:32–36
244. Pastrana B, Mautone AJ, Mendelsohn R (1991) Fourier transform infrared studies of secondary structure and orientation of pulmonary surfactant SP-C and its effect on the dynamic surface properties of phospholipids. Biochemistry 30:10058–10064
245. Pastrana-Rios B, Flach CR, Branner JW, Mautone AJ, Mendelsohn R (1994) A direct test of the ‘‘squeeze-out’’ hypothesis of lung surfactant function: external reflection FT-IR at the air/water interface. Biochemistry 33:5121–5127
246. Pattle RE (1955) Properties, function and origin of the alveolar lining layer. Nature 175:1125–1126
247. Pérez-Gil J, Cruz A, Casals C (1993) Solubility of hydrophobic surfactant proteins in organic solvent/water mixtures: structural studies on SP-B and SP-C in aqueous organic solvents and lipids. Biochim Biophys Acta 1168:261–270
248. Pérez-Gil J, Nag K, Taneva S, Keough KMW (1992) Pulmonary surfactant protein SP-C causes packing rearrangements of dipalmitoyl phosphatidylcholine in spread monolayers. Biophys J 63:197–204
249. Persson A, Chang D, Crouch E (1990) Surfactant protein D is a divalent cation-dependent carbohydrate-binding protein. J Biol Chem 265:5755–5760
250. Persson A, Chang D, Rust K, Moxley M, Longmore W, Crouch E (1989) Purification and biochemical characterization of CP4 (SP-D): a collagenous surfactant-associated protein. Biochemistry 27:6361–6367
251. Persson A, Rust K, Chang D, Moxley M, Longmore W, Crouch E (1988) CP4, a pneumocyte-derived collagenous surfactant-associated protein: evidence for heterogeneity of collagenous surfactant proteins. Biochemistry 27:8576–8584
252. Persson AV, Gibbons BJ, Shoemaker JD, Moxley MA, Longmore WJ (1992) The major glycolipid recognized by SP-D in surfactant is phosphatidylinositol. Biochemistry 31:12183–12189
253. Phizackerley PJR, Town M-H, Newman GE (1979) Hydrophobic proteins of lamellated osmiophilic bodies isolated from pig lung. Biochem J 183:731–736
254. Pikkaar JC, Voorhout WF, van Golde LMG, Verhoef J, van Strijp JAG, van Iwaarden JF (1995) Opsonic activities of surfactant proteins A and D in phagocytosis of Gram-negative bacteria by alveolar macrophages. J Infect Dis 172:481–489
255. Pinkerton KE, Lewis J, Mulder AM, Ikegami M, Jobe AH (1993) Surfactant treatment effects on alveolar type II cell morphology in rabbit lungs. J Appl Physiol 74:1240–1247
256. Pinkerton KE, Lewis JF, Rider ED, Peake J, Chen W, Madi AK, Lun RH, Ikegami M, Jobe AH (1994) Lung parenchyma and type II cell morphometrics: effect of surfactant treatment on preterm ventilated lamb lungs. J Appl Physiol 77:1953–1960
257. Possmayer F (1988) A proposed nomenclature of pulmonary surfactant-associated proteins. Am Rev Respir Dis 138:990–998
258. Possmayer F, Yu S-H, Weber JM, Harding PGR (1984) Pulmonary surfactant. Can J Biochem Cell Biol 62:1121–1133
259. Poulain FR, Allen L, Williams MC, Hamilton RL, Hawgood S (1992) Effects of surfactant apolipo-
proteins on liposome structure: implications for tubular myelin formation. Am J Physiol 262:L730–L739
260. Putnam E, Boere AJF, van Bree L, van Golde LMG, Haagsman HP (1995) Pulmonary surfactant subtype metabolism is altered after short-term ozone exposure. Toxicol Appl Pharmacol 134:132–138
261. Raju TNK, Langenberg P (1993) Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 123:603–610
262. Rana FR, Harwood JS, Mantone AJ, Dluhy RA (1993) Identification of phosphocholine plasmalogens as a lipid component in mammalian pulmonary surfactant using high-resolution 31P NMR spectroscopy. Biochemistry 32:27–31
263. Repka MX, Hardy RJ, Phelps DL, Summers CG (1993) Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol 111:618–620
264. Rice WR, Ross GF, Singleton FM, Dingle S, Whitsett JA (1987) Surfactant-associated protein inhibits phospholipid secretion from type II cells. J Appl Physiol 63:692–698
265. Rider ED, Ikegami M, Whitsett JA, Hull W, Absolom D, Jobe AH (1993) Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits. Am Rev Respir Dis 147:669–676
266. Robertson B (1980) Surfactant substitution: experimental models and clinical applications. Lung 158:57–68
267. Robertson B, Kobayashi T, Ganzuka M, Grossman G, Li W-Z, Suzuki Y (1991) Experimental neonatal respiratory failure induced by a monoclonal antibody to the hydrophobic surfactant-associated protein SP-B. Pediatr Res 30:239–243
268. Rooney SA, Young SL, Mendelson CR (1994) Molecular and cellular processing of lung surfactant. FASEB J 8:957–967
269. Ross GF, Notter RH, Meuth J, Whitsett JA (1986) Phospholipid binding and biophysical activity of pulmonary surfactant-associated protein (SAP)-35 and its non-collagenous COOH-terminal domains. J Biol Chem 261:14283–14291
270. Rüstow B, Haupert R, Stevens PA, Kunze D (1993) Type II pneumocytes secrete vitamin E together with surfactant lipids. Am J Physiol 265:L133–L139
271. Saliba E, Nashashibi M, Vaillant MC, Nasr C, Laugier J (1994) Instillation rate effects of Exosurf on cerebral and cardiovascular haemodynamics in preterm neonates. Arch Dis Child 71:F174–F178
272. Sandberg K, Edberg K-E, Benton W, Silverberg A, Sladek M, Sundell HW (1991) Surfactant improves gas mixing and alveolar ventilation in preterm lambs. Pediatr Res 30:181–189
273. Sano K, Fisher J, Mason RJ, Kuroki Y, Schilling J, Benson B, Voelker D (1987) Isolation and sequence of a cDNA clone for the rat pulmonary surfactant-associated protein (PSP-A). Biochem Biophys Res Commun 144:367–374
274. Schmidt B, Vegh P, Weitz J, Johnston M, Caco C, Roberts R (1992) Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. Am Rev Respir Dis 145:767–770
275. Schmidt-Nielsen K (1979) Animal Physiology: Adaptation and Environment, 2nd Ed. Cambridge University Press, Cambridge
276. Schürch S, Possmayer F, Cheng S, Cockshutt AM (1992) Pulmonary SP-A enhances adsorption and appears to induce surface sorting of lipid extract surfactant. Am J Physiol 263:L210–L218
277. Schürch S, Schürch D, Curschaint, Robertson B (1994) Surface activity of lipid extract surfactant in relation to film area compression and collapse. J Appl Physiol 77:974–986
278. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ (1994) Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 330:1476–1480
279. Seeger WN, Elssner A, Günther A, Krämer H-J, Kalinowski HO (1993) Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am J Respir Cell Mol Biol 9:213–220
280. Seeger W, Grube C, Günther A (1993) Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity. Am J Respir Cell Mol Biol 9:239–247
281. Seeger W, Günther A, Thede C (1992) Differential sensitivity to fibrinogen inhibition of SP-C- vs SP-B-based surfactants. Am J Physiol 261:L286–291
282. Seidner S, Rider E, Jobe A, Yamada T, Ikegami M (1992) Effects of antenatal thyrotropin-releasing hormone, antenatal corticosteroid, and postnatal ventilation on surfactant mobilization in premature rabbits. Am J Obstet Gynecol 166:1551–1559
283. Sen N, Grunstein MM, Chander A (1994) Stimulation of lung surfactant secretion by endothelin-1 from rat alveolar type II cells. Am J Physiol 266:L255–L262
284. Shardonofsky FR, McDonough JM, Grunstein MM (1993) Effects of positive end-expiratory pressure on lung tissue mechanics in rabbits. J Appl Physiol 7:2506–2513
285. Sherman MP, Campbell LA, Merritt TA, Long WA, Gunke JH, Curstedt T, Robertson B (1994) Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J Pediatr 125:939–947
286. Shiffer K, Hawgood S, Haagsman HP, Benson B, Clements JA, Goerke J (1993) Lung surfactant proteins. SP-B and SP-C, alter the thermodynamic properties of phospholipid membranes: a differential calorimetry study. Biochemistry 32:590–597
287. Shimizu H, Miyamura K, Kuroki Y (1991) Appearance of surfactant proteins, SP-A and SP-B, in developing rat lung and the effects of in vivo dexamethasone treatment. Biochim Biophys Acta 1081:53–60
288. Silver RK, MacGregor SN, Farrell EE, Ragin A, Davis C, Socol ML (1993) Perinatal factors influencing survival at twenty-four weeks’ gestation. Am J Obstet Gynecol 168:1724–1731
289. Simatos GA, Forward KB, Morrow MR, Keough KMW (1990) Interaction between perdeuterated dimyristoyl-phosphatidylcholine and low molecular weight pulmonary surfactant protein SP-C. Biochemistry 29:5807–5814
290. Skita V, Kavel SG (1994) The effects of SP-C and cholesterol on pulmonary surfactant monolayers. Am J Respir Crit Care Med 149:95 (abstr)
291. Speer CP, Gefeller O, Groneck P, Lautkötter E, Roll C, Herting E, Boenisch H, Windeler J, Robertson B (1995) Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 72:F8–F13
292. Speer CP, Robertson B, Curstedt T, Halliday HL, et al. (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89:13–20
293. Spragg RG, Gilliard N, Richman P, Smith RM, Hite RD, Pappert D, Robertson B, Curstedt T, Strayer D (1994) Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 105:195–202
294. Stein HM, Oyama K, Martinez A, Chappell BA, Buhl E, Blount L, Padbury JF (1993) Effects of corticosteroids in preterm sheep on adaptation and sympathoadrenal mechanisms at birth. Am J Physiol 264:E763–E769
295. Strayer DS, Hallman M, Merritt TA (1991) Immunogenicity of surfactant. Clin Exp Immunol 83:41–46
296. Stults JT, Griffin PR, Lesikar DD, Naidu A, Moffat B, Benson BJ (1991) Lung surfactant protein SP-C from human, bovine, and canine sources contains palmityl cysteine thioester linkages. Am J Physiol 261:L118–L125
297. Suen HC, Bloch KD, Donahoe PK (1994) Antenatal glucocorticoid corrects pulmonary immaturity in experimentally induced congenital diaphragmatic hernia in rats. Pediatr Res 35:523–529
298. Sun B, Herting E, Curstedt T, Robertson B (1994) Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration. J Appl Physiol 77:1961–1971
299. Sun B, Jobe A, Rider E, Ikegami M (1993) Single dose versus two doses of betamethasone for lung maturation in preterm rabbits. Pediatr Res 33:256–260
300. Survanta Multidose Study Group (1994) Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr 124:962–967
301. Suzuki Y, Fujita Y, Kogishi K (1989) Reconstitution of tubular myelin from synthetic lipids and proteins associated with pig bovine surfactant. Am Rev Respir Dis 140:75–81
302. Takahashi A, Fujitawa T (1986) Proteolipid in bovine lung surfactant: its role in surfactant function. Biochem Biophys Res Commun 135:527–532
303. Taneva SG, Keough KMW (1994) Dynamic surface properties of pulmonary surfactant proteins SP-B and SP-C and their mixtures with dipalmitoylphosphatidylcholine. Biochemistry 33:14660–14670
304. Taneva SG, Keough KMW (1994) Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface. I. Monolayers of pulmonary surfactant protein SP-B and phospholipids. Biophys J 66:1137–1148
305. Taneva SG, Keough KMW (1994) Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface. II. Monolayers of pulmonary surfactant protein SP-C and phospholipids. Biophys J 66:1149–1157
306. Tenner AJ, Robinson SL, Borchelt I, Wright JR (1989) Human pulmonary surfactant protein (SP-A),
307. Thannhauser SJ, Benotti J, Boncoddo NF (1946) Isolation and properties of hydrolecithin (dipalmityl lecithin) from lung: its occurrence in the sphingomyelin fraction of animal tissues. J Biol Chem 166(5):669–675
308. Tsuzuki A, Kuroki Y, Akino T (1993) Pulmonary surfactant protein A-mediated uptake of phosphatidylcholine by alveolar type II cells. Am J Physiol 265:L193–L199
309. Ueda T, Ikekami M, Rider ED, Jobe AH (1994) Distribution of surfactant and ventilation in surfactant-treated preterm lambs. J Appl Physiol 76:45–55
310. van Bel F, de Winter PJ, Wijnands HBG, van de Bor M, Egberts J (1992) Cerebral and aortic blood flow velocity patterns in preterm infants receiving prophylactic surfactant treatment. Acta Paediatr 81:504–510
311. van Daal G-J, Bos JA, Eijken EP, Gommers D, Hannapel E, Lachmann B (1992) Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 145:859–863
312. van der Bleek Y, Plötz FB, van Overbeek FM, Heikamp A, Beeckhuis H, Wildevuur CRH, Okken A, Bambang Oetomo S (1993) Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res 34:154–158
313. van Golde LMG (1995) Potential role of surfactant protein A and D in innate lung defense against pathogens. Biol Neonate 67:2–17
314. van Golde LMG, Batenburg JJ, Robertson B (1988) The pulmonary surfactant system: biochemical aspects and functional significance. Physiol Rev 68:374–455
315. van Iwaarden JF, Pikaar JC, Storm J, Brouwer E, Verhoef J, Oosting RS, van Golde LMG, van Strijp JAG (1994) Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J 303:407–411
316. van Iwaarden JF, Shimizu H, van Golde PHM, Voelker DR, van Golde LMG (1992) Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J 286:5–8
317. van Iwaarden JF, Teding van Berkhout F, Whitsett JA, Oosting RS, van Golde LMG (1995) A novel procedure for the rapid isolation of surfactant protein A with retention of its alveolar macrophage stimulating properties. Biochem J 309:551–555
318. van Iwaarden JF, van Strijp JAG, Ebiskamp MJM, Welmers AC, Verhoef J, van Golde LMG (1991) Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type I by rat alveolar macrophages. Am J Physiol 261:L204–L209
319. van Iwaarden JF, van Strijp JAG, Visser H, Haagsman HP, Verhoef J, van Golde LMG (1992) Binding of surfactant protein A (SP-A) to herpes simplex virus type I-infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem 257:25039–25043
320. van Iwaarden JF, Welmers B, Verhoef J, Haagsman HP, van Golde LMG (1990) Pulmonary surfactant protein A enhances the host defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 2:91–98
321. van ‘t Veen A, Mouton JW, Gommers D, Kluymans JAJW, Dekkers P, Lachmann B (1995) Influence of pulmonary surfactant on in vitro bacterial activities of amoxicillin, cefazidime, and tobramycin. Antimicrob Agents Chemother 39:329–333
322. Vandenbussche G, Clercx A, Clercx M, Curstedt T, Johansson J, Jörnvall H, Ruyschaert J-M (1992) Secondary structure and orientation of the surfactant protein SP-B in a lipid environment: a Fourier transform infrared spectroscopy study. Biochemistry 31:9169–9176
323. Vandenbussche G, Clercx A, Curstedt T, Johansson J, Jörnvall H, Ruyschaert J-M (1992) Structure and orientation of the surfactant protein SP-B in a lipid environment: a Fourier transform infrared spectroscopy study. Biochemistry 31:9169–9176
324. Vaucher YE, Harker L, Merritt TA, Hallman M, Hist K, Bejar R, Heldt GP, Edwards D, Pohjavuori M (1993) Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant. J Pediatr 122:126–132
325. Veldhuizen RAW, Lee J, Sandler D, Hull W, Whitsett JA, Lewis J, Possmayer F, Novick RJ (1993) Alterations in pulmonary surfactant composition and activity after experimental lung transplantation. Am Rev Respir Dis 148:208–215
326. Venkatesh VC, Ianuzzi DM, Ersey R, Ballard PL (1993) Diflucan glucorticoid regulation of the pulmonary hydrophobic surfactant proteins SP-B and SP-C. Am J Respir Cell Mol Biol 8:222–228
327. Venkitaraman AR, Baatz JE, Whitsett JA, Hall SB, Notter RH (1991) Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins. Chem Phys Lipids 57:49–57
328. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrom K, Jacobsen T, Agertoft L, Hobolth N, Djerniee B, Grytter C, Hertel J, Holm V, Hansen US, Kamper J, Svenningsen N, Curstedt T, Bertelsen A, Vestergaard A, Petersen E (1994) Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 331:1051–1055
329. Vilstrup C, Gomers M, Bos JAH, Lachmann B, Werner O, Larsson A (1992) Natural surfactant instilled in premature lambs increases lung volume and improves ventilation homogeneity within five minutes. Pediatr Res 32:595–599
330. Vincent JS, Revak SD, Cochrane CG, Levin IW (1991) Raman spectroscopic studies of model human pulmonary surfactant systems: phospholipid interactions with peptide paradigms for the surfactant protein SP-B. Biochemistry 30:8395–8401
331. Vincent JS, Revak SD, Cochrane CD, Levin IW (1993) Interactions of model human pulmonary surfactants with a mixed phospholipid bilayer assembly: Raman spectroscopic studies. Biochemistry 32:8228–8238
332. Viswell TE, Peabody SS, Davis JM, Slayter MV, Bent RC, Merritt TA (1994) Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndrome. Pediatr Res 36:494–500
333. von Neergaard K (1929) Neue Auffassungen über einen Grund-begriff der Atemmechanik. Z Gesamte Exp Med 66:373–394
334. Voorhout WF, Veenaadl T, Haagmans HP, Verkleij AJ, van Golde LMG, Geuze HJ (1991) Surfactant protein A is localized at the corners of the pulmonary tubular myelin lattice. J Histochem Cytochem 39:1331–1336
335. Voorhout WF, Veenaadl T, Haagmans HP, Weaver TE, Whitsett JA, van Golde LMG, Geuze HJ (1992) Intracellular processing of pulmonary surfactant protein B in an endosomal/lysosomal compartment. Am J Physiol 263:L479–L486
336. Voorhout WF, Weaver TE, Haagmans HP, Geuze HJ, van Golde LMG (1993) The biosynthetic routing of pulmonary surfactant proteins in alveolar type II cells. Microsc. Res. Technique 26:366–373
337. Vorbroker DK, Voorhout WF, Weaver TE, Whitsett JA (1995) Posttranslational processing of surfactant protein C in rat type II cells. Am J Physiol 269:L727–L733
338. Voss T, Eistetter H, Schüfer KP (1988) Macromolecular organization of natural and recombinant lung surfactant protein SP 28–36. J Mol Biol 201:219–227
339. Walther FJ, David-Cu R, Supnet MC, Longo ML, Fan BR, Bruni R (1993) Uptake of antioxidants in surfactant liposomes by cultured alveolar type II cells is enhanced by SP-A. Am J Physiol 265:L330–L339
340. Ward HE, Nicholas TE (1992) Effect of artificial ventilation and anesthesia on surfactant turnover in rats. Respir Physiol 87:115–129
341. Weaver T, Whitsett JA (1991) Function and regulation of expression of pulmonary surfactant-associated proteins. Bioch J 273:249–264
342. Weissbach S, Neuendank A, Pettersson M, Schaberg T, Pison U (1994) Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol 267:L660–L666
343. White RT, Damm D, Miller J, Spratt K, Schilling J, Hawgood S, Benson B, Cordell B (1985) Isolation and characterization of the human pulmonary surfactant apoprotein gene. Nature 317:361–363
344. Whitsett JA, Hull WM, Luse S (1991) Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 87:505–510
345. Whitsett JA, Nogee LM, Weaver TE, Horovitz AD (1995) Human surfactant protein B: structure, function, regulation, and genetic disease. Physiol Rev 75:749–757
346. Wilkie RA, Bryan MH, Tarnow-Mordi WO (1994) Static respiratory compliance in the newborn. II. Its potential for improving the selection of infants for early surfactant treatment. Arch Dis Child 70:F16–F18
347. Williams MC, Hawgood S, Hamilton RL (1991) Changes in lipid structure produced by surfactant proteins SP-A, SP-B, and SP-C. Am J Respir Cell Mol Biol 5:41–50
348. Wright JR, Borchelt JD, Hawgood S (1989) Lung surfactant apoprotein SP-A (26–36 kDa) binds with high affinity to isolated alveolar type II cells. Proc Natl Acad Sci USA 86:5410–5414
349. Wright JR, Dobbs LG (1991) Regulation of pulmonary surfactant secretion and clearance. Annu Rev Physiol 53:395–414
350. Wright JR, Wager RE, Hawgood S, Dobbs L, Clements JA (1987) Surfactant apoprotein Mr = 26,000–36,000 enhances uptake of liposomes by type II cells. J Biol Chem 262:2888–2894
351. Wright JR, Youmans DC (1993) Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophage. Am J Physiol 264:L338–L344
352. Wright JP, Youmans DC (1995) Degradation of surfactant lipids and surfactant protein A by alveolar macrophages in vitro. Am J Physiol 268:772–780
353. Yan C, Sever Z, Whitsett JA (1995) Upstream enhancer activity in the human surfactant protein B gene is mediated by thyroid transcription factor 1. J Biol Chem 270:24852–24857
354. Young SL, Wright JR, Clements JA (1989) Cellular uptake and processing of surfactant lipids and apoprotein SP-A by rat lung. J Appl Physiol 66:1336–1342
355. Yu S-H, Possmayer F (1992) Effect of pulmonary surfactant protein B (SP-B) and calcium on phospholipid adsorption and squeeze-out of phosphatidylglycerol from binary phospholipid monolayers containing dipalmitoylphosphatidylcholine. Biochim Biophys Acta 1126:26–34
356. Yu S-H, Possmayer F (1992) Studies on surfactant-associated protein B-mediated adsorption of surfactant phospholipids. Am Rev Respir Dis 145:874 (abstr)
357. Yukitake K, Brown CL, Schluter MA, Clements JA, Hawgood S (1995) Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 37:21–25
358. Zola EM, Gunel JH, Chan RK, Lim MO, Knox I, Feldman BH, Denson SE, Stonestreet BS, Mitchell BR, Wyza MM, Bennett KJ, Gold AJ (1993) Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 122:453–459

Accepted for publication: 8 July 1996